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ABSTRACT 
Panu Uusalo 
Pharmacokinetics and effects of extravascularly administered dexmedetomidine 
Studies on Pediatric and Adult Patients, and Healthy Adult Volunteers 
University of Turku; Faculty of Medicine; Anaesthesiology, Intensive Care, Emergency 
Care and Pain Medicine; Drug Research Doctoral Programme; Perioperative Services, 
Intensive Care and Pain Medicine; Turku University Hospital 
Annales Universitatis Turkuensis, Medica-Odontologica, Turku, Finland, 2019 
Patients undergoing surgery and other invasive procedures need sedation and pain relief. Many 
unpleasant sensations and experiences can be reduced by administration of conventional 
sedative and analgesic drugs, but most of these compounds are associated with troublesome 
adverse effects such as respiratory depression and nausea.  
Dexmedetomidine is a relatively new drug that acts by activating α2-adrenoceptors. It has 
received marketing authorisation for intensive care sedation and for procedural sedation of adult 
patients. In addition to its sedative property, dexmedetomidine exerts analgesic and antiemetic 
effects. In comparison to other analgesic and sedative agents, dexmedetomidine has minimal 
effects on respiration. 
Dexmedetomidine has been developed and approved for intravenous administration. Several 
reports exist on the use of intranasal and other extravascular routes of administration of 
dexmedetomidine. Nonetheless, the pharmacokinetic and pharmacodynamic properties of 
extravascularly administered dexmedetomidine have remained poorly characterized. The 
intranasal route of administration appears to be feasible for administration of dexmedetomidine 
to children, but there is rather little information available about the pharmacokinetics of 
dexmedetomidine in children. 
In the present series of studies, the pharmacokinetics and -dynamics of subcutaneously and 
intranasally administered dexmedetomidine were characterized in healthy volunteers and in 
pediatric patients. We also evaluated the anesthetic sparing effect of intranasally administered 
dexmedetomidine in pediatric patients undergoing ambulatory sedation, and the analgesic 
sparing effect of intranasally administered dexmedetomidine in adult patients undergoing hip 
arthroplasty under general anesthesia.  
The systemic bioavailability of subcutaneously administered dexmedetomidine was good (81%), 
but interindividual variation was large. After intranasal administration of dexmedetomidine in 
pediatric patients, on average the peak plasma concentrations were achieved in 37 minutes, with 
peak effects normally observed at 45 minutes. Peak concentrations and exposure to the study drug 
decreased with age. Intranasal doses of 2-3 µg/kg achieved clinically acceptable sedation in about 
94% of pediatric patients undergoing magnetic resonance imaging. In adult patients undergoing 
total hip arthroplasty, the use of intranasal low-dose dexmedetomidine decreased postoperative 
opioid consumption in a clinically significant manner. 
Our findings provide support for the use of intranasal dexmedetomidine in pediatric patients 
requiring light or moderate sedation and in adult patients undergoing painful surgical 
procedures. Subcutaneous administration of dexmedetomidine appears promising e.g. for 
patients needing palliative sedation and analgesia, but further studies are warranted to confirm 
this proposal.   
Keywords: dexmedetomidine, subcutaneous, intranasal, pharmacokinetics, 
pharmacodynamics  
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TIIVISTELMÄ 
Panu Uusalo 
Ekstravaskulaarisesti annostellun deksmedetomidiinin farmakokinetiikka ja 
vaikutukset 
Tutkimuksia aikuis- ja lapsipotilailla sekä terveillä vapaaehtoisilla aikuisilla 
Turun yliopisto; Lääketieteellinen tiedekunta; Anestesiologia ja Tehohoito; Lääke-
tutkimuksen tohtoriohjelma; Toimenpide-, tehohoito- ja kivunhoitopalvelut, Turun 
yliopistollinen keskussairaala 
Annales Universitatis Turkuensis, Medica-Odontologica, Turku, Finland, 2019 
Leikkauksiin ja muihin toimenpiteisiin tulevat potilaat tarvitsevat rauhoittavaa ja kipua 
lievittävää lääkitystä. Vaikka monia epämiellyttäviä oireita ja tuntemuksia voidaan lievittää 
tavanomaisilla kipu- ja rauhoittavilla lääkkeillä, liittyy niiden käyttöön usein hankalia 
haittavaikutuksia kuten hengityslamaa ja pahoinvointia. 
Deksmedetomidiini on uudehko aikuisten tehohoito- ja toimenpidepotilaiden rauhoitta-
miseen myyntiluvan saanut, α2-adrenoseptoreja aktivoiva lääkeaine, jolla on väsyttävä ja 
potilasta rauhoittava vaikutus, mutta lisäksi myös kipua ja pahoinvointia lieventäviä 
vaikutuksia. Deksmedetomidiinin etu verrattuna tavanomaisiin kipu- ja rauhoittaviin 
lääkkeisiin on sen hyvin vähäinen vaikutus potilaan hengitykseen.  
Deksmedetomidiini on kehitetty ja tarkoitettu annosteltavaksi laskimoon. Monia muitakin 
annostelureittejä, kuten annostelua nenän limakalvoille, on tutkittu. Deksmedetomidiinin 
annostelusta muuten kuin laskimon kautta on tehty kuitenkin vain vähän farmakokineettisiä 
ja farmakodynaamisia tutkimuksia. Vaikka annostelua nenän limakalvolle käytetäänkin jo 
lapsipotilailla varsin usein, ei sen imeytymistä ja käyttäytymistä elimistössä ole lapsipotilailla 
juurikaan tutkittu.  
Tässä tutkimussarjassa verrattiin ihon alle ja laskimoon annostellun deksmedetomidiinin 
farmakokinetiikkaa ja -dynamiikkaa terveillä vapaaehtoisilla aikuisilla sekä tutkittiin nenän 
limakalvoille annostellun deksmedetomidiinin farmakokinetiikkaa ja -dynamiikkaa 
lapsipotilailla. Tutkimme lisäksi nenän limakalvoille annostellun deksmedetomidiinin 
vaikutusta nukutuslääkkeen tarpeeseen sedaatiota tarvitsevilla lapsipotilailla sekä 
yleisanestesiassa tehdyn lonkkaproteesileikkauksen jälkeiseen kipulääkkeen tarpeeseen 
aikuispotilailla.  
Ihon alle annostellun deksmedetomidiinin hyötyosuus osoittautui hyväksi (81 %), mutta 
yksilöiden välinen vaihtelu oli suurta. Lapsipotilailla nenän limakalvoille annostellun 
deksmedetomidiinin huippupitoisuus plasmassa saavutettiin 37 min ja huippuvaikutus 45 
min kuluttua lääkkeen annostelusta. Huippupitoisuus ja altistus lääkkeelle pienenivät iän 
myötä. Nenän limakalvoille annosteltu deksmedetomidiini aiheutti merkittävän sedaation 
annoksella 2-3 µg/kg. Aikuispotilailla nenän limakalvoille annosteltu pieniannoksinen 
deksmedetomidiini vähensi leikkauksen jälkeisen opioidikipulääkkeen tarvetta. 
Löydöksemme kannustavat käyttämään nenän limakalvoille annosteltua deksmedeto-
midiinia lapsipotilailla, jotka tarvitsevat kevyttä tai kohtalaista sedaatiota, sekä 
aikuispotilailla, joille tehdään kivuliaita leikkauksia. Myös ihon alle annosteltu 
deksmedetomidiini vaikuttaa lupaavalta esim. palliatiivista hoitoa saaville potilaille, mutta 
annostelusta tarvitaan lisää kliinisiä tutkimuksia. 
Avainsanat: deksmedetomidiini, ihonalainen, intranasaalinen, farmakokinetiikka, 
farmakodynamiikka 
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I  INTRODUCTION 
The most important reasons why many patients need sedation during perioperative 
care are pain management, patient comfort and patient and personnel safety. 
Sedation may also be needed when attempting various interventions, such as to 
facilitate the management of respiratory problems (Devlin 2008). Conventional 
sedative drug regimens in the intensive and perioperative care settings have primarily 
consisted of GABAA receptor modulators such as propofol, benzodiazepines and 
barbiturates (Devlin and Roberts 2011). Opioids are also widely used to treat pain 
and to facilitate procedures that require sedation. Both GABAA modulators and 
opioids carry a risk of respiratory depression and may predispose patients to 
respiratory complications as well as to increased morbidity and mortality. 
Furthermore, these agents are challenging to use for long-term sedation, because they 
may accumulate in an unpredictable manner (Kollef et al. 1998, Swart et al. 2006, 
Barr et al. 2001). α2-Adrenoceptor agonists are now challenging the traditional 
sedative agents since they inhibit neuronal activity by a unique mechanism of action, 
evoking sedative and analgesic effects and centrally mediated sympatholysis. α2-
Adrenoceptor agonists are already in worldwide use as components of multimodal 
procedural and intensive care sedation and analgesia (Wujtewicz et al. 2003, Aantaa 
et al. 2015, Helander 2017). 
Several α2-adrenoceptor agonist drugs have been employed for patient sedation in 
the intensive care and perioperative care settings. Dexmedetomidine is the most 
selective and specific of the currently available α2-adrenoceptor agonists. Compared 
to clonidine, another widely used α2-adrenoceptor agonist, the α2-/α1-selectivity ratio 
of dexmedetomidine is approximately eight-fold (1600:1). Dexmedetomidine has 
been registered in approximately 70 countries for continuous intravenous infusion 
for sedation of intubated and mechanically ventilated adult patients in intensive care 
units (ICU). Additionally, dexmedetomidine also has approval for procedural 
sedation in some countries (Orion corp. 2018, Marko Hannula, Orion Pharma, e-
mailed personal communication February 15th 2019).  
Dexmedetomidine is often administered as a continuous intravenous infusion (Orion 
corp. 2018). In addition, many investigator-initiated clinical studies have reported 
on the extravascular administration of dexmedetomidine, with intramuscular 
injections and intranasal administration being the most extensively investigated; 
there is convincing evidence to support the intranasal use of dexmedetomidine. 
However, detailed pharmacokinetic information has been lacking on these delivery 
routes, and therefore further studies are warranted in order to ensure that 
extravascular administration of dexmedetomidine is both safe and practical. Any 
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delivery mode other than intravenous use of dexmedetomidine is currently 
considered off-label (Karaaslan et al. 2006, Iirola et al. 2011a) 
There are several published case reports and uncontrolled studies (Soares et al. 
2002, Kent et al. 2005) indicating that dexmedetomidine may provide benefits for 
patients in palliative care as it induces analgesia, sympatholysis and sedation with 
relatively little risk of respiratory depression. Intravenous administration of 
analgesic or sedative agents is often unsuitable for palliative care patients, and 
alternative administration routes are beneficial but before extravascular 
administration routes can become routine, there must be evidence from 
pharmacokinetic and pharmacodynamic studies that they are feasible. 
No current sedative agent appears to be ideally suited for procedural sedation of 
pediatric patients. Although dexmedetomidine does not have regulatory approval for 
use in this population, it is quite commonly used for pediatric ICU sedation. 
Increasingly, many pediatric operation units use dexmedetomidine as premedication 
and as an anesthetic adjunct (Mason and Lerman 2011). Since developmental and 
physiological changes in children contribute to the age-related variation in drug 
disposition (Thakkar et al. 2017), clinical evaluations on the pharmacokinetic and 
pharmacodynamic properties of dexmedetomidine in pediatric patients are clearly 
warranted. 
In the present series of studies, we characterized the pharmacokinetics and 
pharmacodynamics of subcutaneously and intranasally administered 
dexmedetomidine in healthy adult volunteers and in pediatric patients. We also 
examined whether intranasally administered dexmedetomidine would have 
anesthetic-sparing effects in pediatric patients undergoing ambulatory sedation and 
analgesic-sparing effects in adult patients undergoing hip arthroplasty under general 
anesthesia.  
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II  REVIEW OF THE LITERATURE 
2.1  Alpha-adrenoceptors 
2.1.1  History and classification of adrenoceptors 
Adrenoceptors are membrane-bound G-protein coupled receptors that are located on 
neurons and non-neuronal cell membranes throughout the body. Adrenoceptors bind 
and are activated by two endogenous catecholamines, adrenaline and noradrenaline, 
but are also targeted by many synthetic therapeutic agents (Maze and Regan 1991). 
Adrenoceptors have been extensively investigated as they are mediators of many 
physiologically important effects e.g. the regulation of endocrine, neuronal, vascular 
and metabolic activities. Already in 1948, these receptors were divided into two main 
types, α- and β-adrenoceptors, based on the rank order of potency of various natural 
and synthetic catecholamines in different physiologic test preparations. At that time, 
α-adrenoceptors were considered to mediate the excitatory effects of catecholamines 
whereas β-adrenoceptors were considered to mediate inhibitory effects (Ahlquist et 
al. 1948). 
In 1974, Langer et al. presented the concept that α1-adrenoceptors were excitatory 
and mediated postsynaptic responses to catecholamines in target organs, whereas 
presynaptically located α2-adrenoceptors evoked inhibitory effects by preventing the 
release of noradrenaline from nerve endings (Langer et al. 1974). Further studies, 
however, revealed that α-adrenoceptors could not be classified based on their 
anatomical locations alone, but instead a subdivision was devised according to the 
functions mediated by each type of receptor and their respective ligands (Berthelsen 
and Pettinger 1977). 
In 1967, the β-adrenoceptors were divided into two subtypes, β1 and β2 (Lands et al. 
1967), and during the 1980s, the research group of Lefkowitz and Kobilka managed 
to identify the gene that encodes the β2-adrenoceptor. This research revealed that the 
receptor consisted of seven hydrophobic spiral strings that were each long enough to 
span the cell membrane – so-called α-helices (Dixon et al. 1986). Three decades 
later, Kobilka’s research group was able to capture an image of the β2-adrenoceptor 
at the very moment when it transferred the signal from the hormone on the outside 
of the cell to the G-protein inside the cell (Rasmussen et al. 2011). This research was 
honoured with the award of Nobel Prize in Chemistry in 2012 (Benovic 2012). 
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Advances made with molecular biological techniques and radioligand binding assays 
have helped to clarify the subtypes of adrenoceptors (Aantaa et al. 1995). In 1994, 
radioligand binding experiments revealed that there were four pharmacologically 
distinct subtypes of α2-adrenoceptors, α2A, α2B, α2C and α2D (Bylund et al. 1994), but 
later studies revealed that human α2A- and rat α2D-adrenoceptors were encoded by 
splicing variants of the same α2A-adrenoceptor gene. Today, it is known that the 
adrenoceptor family includes nine different gene products in mammals: three β- (β1, 
β2 and β3), three α1- (α1A, α1B, α1D) and three α2-adrenoceptors (α2A, α2B and α2C) 
(Cotecchia et al. 2010) (Figure 1). The α1- and α2-adrenoceptor subtypes are located 
in various organs, including heart, blood vessels, brain, kidney, liver and spleen. In 
most tissues, activation of α1-adrenoceptors triggers polyphosphoinositide 
hydrolysis catalyzed by phospolipase C via pertussis toxin-insensitive G-proteins 
(Graham et al. 1996). The most important therapeutic effect of α1-adrenoceptor 
activation is vasoconstriction and increased blood pressure. β-Adrenoceptor 
subtypes mediate the actions of catecholamines and many therapeutic agents, via 
adenylate cyclase stimulation through heterotrimeric Gs-proteins, by increasing 
intracellular concentrations of cAMP and by regulating L-type calcium channels in 
the cell membrane, leading to the characteristic physiological responses such as 
smooth muscle relaxation and bronchodilation (Yu et al. 1993). 
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Figure 1. The adrenoceptor family. 
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2.1.2  α2-Adrenoceptors 
The best known function of α2-adrenoceptors is to mediate the physiological 
feedback inhibition of noradrenaline release from nerve endings. α2-Adrenoceptors, 
located on presynaptic sympathetic neuronal membranes, inhibit the release of 
neurotransmitters from vesicles containing noradrenaline and several co-
transmitters, including neuropeptide Y and ATP; these receptors are called 
autoreceptors (Burnstock et al. 1990). Presynaptic release-modulating α2-
adrenoceptors that are located on cells releasing other neurotransmitters than 
noradrenaline are often called heteroreceptors (Starke et al. 2001). 
All three α2-adrenoceptor subtypes share similar signaling properties (Limbird et al. 
1988). The most obvious functionally important differences between the three α2-
adrenoceptor subtypes are their different cellular and tissue localizations that result 
in different physiological functions and pharmacological activity. All α2-
adrenoceptor subtypes are able to inhibit endogenous transmitter release from 
postganglionic sympathetic neurons (Trendelenburg et al. 2003), but differ in their 
pharmacological properties, sensitivity to phosphorylation, desensitization and 
internalization (Philipp et al. 2002). 
Specific physiological functions of α2-adrenoceptor subtypes have been identified in 
the peripheral nervous system, in the central nervous system, and in a variety of 
organs and cell types, including the liver, pancreas, kidney, blood platelets and eyes 
(Szabo et al. 1989). α2A-Adrenoceptors are expressed widely in the central nervous 
system, especially in noradrenergic cell body regions such as the locus coeruleus in 
the brain stem (Scheinin et al. 1994, MacDonald and Scheinin 1995). α2A-
Adrenoceptors have also been found in the prefrontal cortex, perhaps explaining why 
α2A-adrenoceptor agonists may be beneficial in the treatment of attention deficit and 
hyperactivity disorder (Ma et al. 2015). Peripheral locations where α2A-
adrenoceptors are the dominant subtype are human blood platelets, aorta and spleen. 
α2B -Adrenoceptors have been found to be sparsely expressed in the central nervous 
system, although with relatively most abundant expression in the thalamus. In the 
periphery, α2B-adrenoceptors are present in heart and liver (MacDonald and Scheinin 
1995, Wang et al. 2002, Gyires et al. 2009). The α2C-subtype is the dominant α2-
adrenoceptor subtype in the spinal cord, although the spinal cord appears to express 
all three subtypes. Examples of the tissue localizations and physiological functions 
of the three α2-adrenoceptor subtypes are summarized in Table 1. 
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Table 1. Examples of the tissue localizations, physiological functions and pharmacological 
responses of α2-adrenoceptor subtypes. 
Receptor Localizations Physiological functions and responses 
α2A Locus coeruleus, Pontine nuclei, 
Midbrain, Cerebral cortex, Amygdaloid 
complex, Hypothalamus, Spinal cord, 
Platelets, Aorta, Spleen, Kidney, 
Vascular smooth muscle, Endothelium 
Presynaptic inhibition of 
neurotransmitter release, Hypotension, 
Bradycardia, Sedation, Anesthetic 
sparing effect, Hypothermia, 
Antinociception, Inhibition of gastric 
emptying, Vascular smooth muscle 
contraction, Platelet aggregation 
α2B Thalamus, Lungs, Vascular smooth 
muscle, Kidneys, Uterus 
Vascular smooth muscle contraction, 
Hypertension, Bradycardia, Salt-induced 
hypertension 
α2C Cerebral cortex, Basal ganglia, 
Hippocampus, Spinal cord, Vascular 
smooth muscle, Kidneys, Olfactory 
system 
Presynaptic inhibition of 
neurotransmitter release, Hypothermia, 
Antinociception, Vascular smooth 
muscle contraction  
Modified from Blaxall et al. 1994, MacDonald and Scheinin 1995, Hunter et al. 1997, Trendelenburg et al. 
2003, Gyires et al. 2009 and Gilsbach et al. 2011 
The α2-adrenoceptors are coupled to pertussis-toxin-sensitive Gα0-proteins that 
regulate ion channels and Gαi-proteins that mediate inhibition of adenylyl cyclases 
(Freissmuth et al. 1989). When an agonist binds to a G-protein coupled α2-
adrenoceptor, the receptor structure becomes slightly altered, leading to a 
conformational change in the associated α-subunit of the G-protein. Activation of Gαi-
protein inhibits intracellular adenylyl cyclase enzymes, which in turn leads to reduced 
formation of the second messenger, cAMP. This regulates many important cellular 
functions by controlling the phosphorylation state of regulatory proteins via a cAMP-
dependent protein kinase, protein kinase A (Birnbaumer et al. 1990). Activation of α2A-
adrenoceptors evokes centrally mediated inhibition of the peripheral sympathetic 
nervous system, which can be seen as diminished catecholamine levels in plasma. The 
ensuing attenuation of the neuroendocrine and hemodynamic responses to anesthesia 
and surgery is often beneficial (Gertler et al. 2001). 
2.1.3  α2-Adrenoceptor agonists 
In 1960, the German pharmaceutical company Boehringer-Ingelheim was 
developing a novel drug to be marketed as a nasal decongestant. When used to treat 
the symptoms of common cold in one of the laboratory staff members, a drop of a 
0.3% solution of this 2,6-dichloro-substituted imidazole compound (clonidine) was 
administered into both nostrils. Unexpectedly, the subject fell asleep and developed 
low blood pressure, marked bradycardia and dryness of the mouth. Thereafter, this 
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drug molecule’s decongestant properties were considered to be far less interesting 
than its potent anti-hypertensive activity, and as a result, clonidine was introduced 
in 1966 for the treatment of hypertension (Stähle et al. 2000). 
Later, many therapeutic indications have emerged for α2-adrenoceptor agonist drugs. 
The imidazole derivatives xylazine, detomidine and medetomidine have been used 
in veterinary sedation for almost 40 years (Tranquilli et al. 1992). Off-label use of 
clonidine has extended to sedation and analgesia of critically ill patients and to its 
use as an anesthetic and intrathecal adjunct (Wang et al. 2017, Crespo et al. 2017). 
In the year 2000, clonidine received approval from the FDA for the treatment of 
Attention Deficit Hyperactivity Disorder in children aged 6-17 years (Sallee et al. 
2013). Clonidine has also been used in the treatment of opioid and alcohol 
withdrawal symptoms (Gowing et al. 2016). Apraclonidine and brimonidine are used 
as eye drops to treat glaucoma (Arthur et al. 2011). Tizanidine has been found to be 
equally effective but better tolerated than some other anti-spasticity drugs such as 
baclofen and diazepam in the treatment of neurological patients (Kamen et al. 2008). 
Rilmenidine and moxonidine are used as antihypertensives: these compounds have 
been postulated to exert their pharmacological effects by activating imidazole 
receptors in addition to being α2-adrenoceptor agonists (Khan et al. 1999). 
2.1.4  α2-Adrenoceptor antagonists 
In veterinary medicine, the α2-adrenoceptor agonists xylazine, detomidine, 
medetomidine and dexmedetomidine are commonly used for sedation and analgesia, 
and atipamezole, an α2-adrenoceptor antagonist, has been used to reverse their effects 
when sedation is no longer needed (Aantaa et al. 1995). In addition, Karhuvaara et 
al (1991) administered atipamezole intravenously to human volunteers in order to 
reverse the effects of dexmedetomidine. Atipamezole, the most selective α2-
adrenoceptor antagonist then available, was able to reverse the sedation and 
hypotension evoked by dexmedetomidine (Karhuvaara et al. 1991).  
2.2  Dexmedetomidine 
2.2.1  Molecule and history 
Dexmedetomidine (4-[(1S)-1-(2,3-dimethylphenyl)-ethyl]-1H-imidazole), an 
imidazole compound (Figure 2), is the pharmacologically active dextroisomer of 
medetomidine, with the molecular formula C13H16N2. Dexmedetomidine has a pKa 
of 7.1 and a logP of 2.9. Its hydrochloride salt is freely soluble in water. The 
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molecular weight of dexmedetomidine hydrochloride is 236.7 g/mol. It is a highly 
selective α2-adrenoceptor agonist with a relatively high selectivity ratio for α2/α1-
adrenoceptors (1620:1 as compared to 220:1 for clonidine) (Orion corp. 2018). The 
lipid solubility of dexmedetomidine is 3.5 times higher than that of clonidine, which 
enables it to diffuse more easily into the central nervous system. Its high lipophilicity 
and relatively rapid elimination mean that the drug has an excellent spectrum of 
effects i.e. efficacy, a good safety profile with a very rapid onset of action and a short 
duration of clinical effects (Grosu et al. 2010).  
Dexmedetomidine was originally developed by the Finnish pharmaceutical research 
and development company, Farmos Pharma. In the 1980s, Farmos Pharma was 
conducting human pharmacological studies with racemic medetomidine. Since the 
drug authorities were already at that time favoring the use of active enantiomers, 
dexmedetomidine was developed and administered for the first time to healthy 
human volunteers in 1987. The aim was to develop a drug that could be used as 
anesthesia premedication before medical procedures (Kallio et al. 1989). The 
sedative, sympatholytic and hemodynamic effects of dexmedetomidine were 
documented already in the first clinical studies. At the beginning of the 1990s, 
dexmedetomidine was administered intramuscularly to hundreds of patients 
(Scheinin et al. 1992, Scheinin et al. 1993, Dyck et al. 1993a). These studies have 
later been considered as phase II-III studies. At the same time, many investigators 
became interested in the possible cardioprotective effects of dexmedetomidine 
(Bloor et al. 1992, Dyck et al. 1993b). The sympatholytic effect of dexmedetomidine 
was thought to stabilize intraoperative changes in blood pressure and HR, thus they 
could help to prevent cardiac ischemia. Perioperative infusions of dexmedetomidine 
were found to be beneficial in the perioperative hemodynamic management of 
patients undergoing vascular surgery (Talke et al. 1995).  
Dexmedetomidine was introduced into clinical practice in the United States in 1999 
and was at that time approved by the FDA only for short-term (<24 hours) sedation 
of mechanically ventilated adult patients in the ICU. At the same time, the EMA was 
not willing to approve dexmedetomidine since all controlled clinical trials had been 
conducted with only placebo as comparator. Based on two extensive phase III 
clinical trials, PRODEX and MIDEX, a product called Dexdor® received European 
marketing authorisation in September 2011 (Kallio and Aantaa 2012). The PRODEX 
and MIDEX trials showed that dexmedetomidine was successful in reducing the 
duration of mechanical ventilation compared with midazolam, but tended not to be 
inferior to the standard sedatives, propofol and midazolam, in maintaining light to 
moderate sedation (Jakob et al. 2012). In 2018, dexmedetomidine received an 
indication for sedation of non-intubated adult patients prior to and/or during 
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diagnostic or surgical procedures requiring sedation (i.e. procedural/awake sedation) 
in Finland and many other countries (Orion corp. 2018). Several published reports 
exist regarding off-label use of dexmedetomidine as an adjunctive anesthetic and 
analgesic during general anesthesia (Piao et al. 2014, Wu et al. 2016) and in treating 
alcohol and opioid withdrawal symptoms (Wong et al. 2015, Oschman et al. 2011). 
Dexmedetomidine has also been described as a useful and safe adjunct in many other 
clinical applications, such as treating glaucoma, reducing sympathetic overactivity, 
alleviating withdrawal symptoms or pain in the terminal stages of life (Gilsbach and 
Hein 2012, Jackson et al. 2006). Off-label use of dexmedetomidine in the pediatric 
patient population is very common and this will be discussed in Chapter 2.5. 
2.2.2  Pharmacokinetics of dexmedetomidine 
After intravenous administration to healthy human volunteers, dexmedetomidine has 
been shown to have a distribution half-life of approximately 6 min (Karol and Maze 
2000). One-, two- and three-compartment disposition models have been used to 
describe the pharmacokinetics of dexmedetomidine (Talke et al. 1997, Venn et al. 
2002, Lin et al. 2011, Iirola et al. 2012, Välitalo et al. 2013).  
In plasma, dexmedetomidine is bound to albumin and α1-acid-glycoprotein. The 
average extent of protein binding is 94%; some displacement from plasma protein 
binding sites has been reported by fentanyl, ketorolac, theophylline, digoxin and 
lidocaine, all of which are drugs commonly used during anesthesia and in the ICU 
(Gertler et al. 2001). In healthy volunteers, the apparent volume of distribution has 
been reported to be approximately 1.31–2.46 L/kg at steady state. In the critically ill, 
these values are far more variable, with mean volumes of distribution ranging from 
109 to 223 L (Weerink et al. 2017). 
Although dexmedetomidine has only approval for intravenous administration, its 
bioavailability has been investigated after administration by various extravascular 
routes i.e. intramuscular, transdermal, buccal, intranasal and peroral administration 
(Scheinin et al. 1992, Dyck et al. 1993a, Kivistö et al. 1994, Anttila et al. 2003, Iirola 
et al. 2011a). The pharmacokinetic properties of extravascularly administered 
dexmedetomidine are summarized in Table 2, and the various extravascular 
administration routes of dexmedetomidine are discussed more comprehensively in 
Chapter 2.6.  
The major metabolic pathways of dexmedetomidine are direct N-glucuronidation to 
form inactive conjugated metabolites, oxidation and hydroxylation, primarily 
mediated by CYP2A6, and N-methylation (Figure 2). The most abundant circulating 
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metabolites of dexmedetomidine are two isomeric N-glucuronides (G-Dex-1 and G-
Dex-2) (41%). Metabolite H-1, N-methyl 3-hydroxymethyl dexmedetomidine O-
glucuronide, is also a major circulating product of dexmedetomidine 
biotransformation (21%). Cytochrome P-450 enzymes catalyse the formation of two 
minor circulating metabolites, H-3 is produced by oxidation of the imidazole ring 
(11%) and 3-hydroxymethyl dexmedetomidine results from the hydroxylation at the 
drug’s 3-methyl group (Ji et al. 2004, Orion Corp. 2018). There is also some data 
suggesting that the formation of the oxidised metabolites is mediated by several CYP 
isoforms (CYP2A6, CYP1Α2, CYP2E1, CYP2D6 and CYP2C19). These 
metabolites have negligible pharmacological activity (Karol and Maze 2000). 
Dexmedetomidine is mainly eliminated through biotransformation in the liver and 
less than 1% of a dose is excreted unchanged in urine and faeces. After intravenous 
infusion of 2 µg/kg of radioactive [3H]-dexmedetomidine, 95% of the total 
radioactivity was found in the urine and only 4% in the faeces (Karol and Maze 
2000). A hepatic extraction ratio of 0.7 has been reported (Dutta et al. 2000). In 
healthy volunteers, the average terminal half‐life has been reported to be 2.0-3.1 h 
and CL 0.5-0.8 l/min (Venn et al. 2002, Anttila et al. 2003, Iirola et al. 2011). 
Dexmedetomidine has major effects on cardiovascular function, potentially causing 
bradycardia, hypotension or transient hypertension that may impact on its own 
pharmacokinetics. At high plasma concentrations, marked vasoconstriction occurs, 
which may well reduce the drug’s volume of distribution. Dutta et al (2000) used a 
computer-controlled infusion protocol and investigated the effect of cardiac output 
on the elimination of dexmedetomidine. Increasing plasma concentrations of 
dexmedetomidine decreased cardiac output, resulting in a corresponding decrease in 
drug elimination CL by ≤ 12%, but the decrease in dexmedetomidine CL was not 
regarded as clinically relevant in the therapeutic concentration range (Dutta et al. 
2000). Dexmedetomidine decreases hepatic blood flow, which may have an impact 
on the CL of some drugs, at least in theory. 
Table 2. Previous pharmacokinetic human studies of extravascular administration of dexmedetomidine. 
Author and year Scheinin 1992 Dyck 1993a Kivistö 1994 Anttila 2003 Iirola 2011a Li 2018 Miller 2018 
Administration 
route IM IM, IV TD, IV PO, buccal, IM, IV IN, IV IN, IV IN, IV 
Subjects Male volunteers Male volunteers 
Healthy 
males Healthy males 
Male 
volunteers 
Healthy 
adults 
Pediatric 
patients 
No of subjects 6 10 9 12 6 8 12 
Dose 0.5, 1.0, 1.5 ug/kg 2.0 ug/kg 625 ug/12 h 2.0 ug/kg 84 ug 1.0 ug/kg 1.0-2.0 ug/kg 
Tmax (min)* 96-102 13 N/A 72, 114 and 132 38 60 46 
Cmax (ng/ml)* 0.14, 0.26, 0.34 0.80 N/A 0.11, 0.29 and 0.51 0.34 0.25 - 0.28 0.18 - 0.32 
F* N/A 73% 51% 16%, 82%, 104% 65% 41% 82% 
* Corresponding parameters after extravascular administration reported, IM; intramuscular, IN; intranasal, IV; intravenous, PO; per oral, TD; transdermal 
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Figure 2. The structural formula of dexmedetomidine and the first steps in its proposed metabolic 
scheme. 
*stereocentre 
2.2.3  Pharmacokinetics in special populations 
Age, gender and race 
In a phase I pre-registration study conducted by Abbott Laboratories, no differences 
were found in the pharmacokinetics of dexmedetomidine in healthy volunteers 
between groups of young (18–40 years), middle-aged (41–65 years) and elderly (>65 
years) subjects (Hospira Inc. 2016). In critically ill patients, age was found to be a 
covariate for dexmedetomidine pharmacokinetics, but results on this issue have been 
inconsistent and no definitive conclusions about the findings can be made (Iirola 
2012, Lee et al. 2012, Kuang et al. 2016). Elimination of dexmedetomidine in 
children (1 months to 17 years) appears similar to that in adults, but in newborn 
infants (under 1 month), it may be slower (Hospira Inc. 2016). No major 
pharmacokinetic differences have been observed between the sexes. There is only 
little evidence of ethnic differences in the metabolism of dexmedetomidine (Kurnik 
et al. 2011).  
* 
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Hepatic and renal impairment 
Dexmedetomidine is mainly metabolized by the liver, and its plasma protein binding 
may be decreased in subjects with hepatic impairment as compared to healthy 
subjects. In a pre-registration study conducted by Abbott Laboratories, mean CL 
estimates in patients with mild, moderate, and severe hepatic impairment (Child-
Pugh Class A, B, or C) were 74, 64, and 53% of those found in healthy subjects. The 
mean elimination half-life of dexmedetomidine in healthy subjects was 2.5 h and it 
was prolonged to 3.9, 5.4, and 7.4 h in patients with mild, moderate, and severe 
hepatic impairment, respectively (Weerink et al. 2017). 
Rolle et al (2018) investigated the pharmacokinetics of intraoperatively administered 
dexmedetomidine in forty patients undergoing abdominal laparoscopy. Hepatic 
blood flow, liver histopathology, liver enzymes, and gene expression of some 
metabolizing enzymes (UGT2B10 and µgT1A4) were tested as covariates of 
dexmedetomidine metabolic CL; liver blood flow was found to be a covariate for 
dexmedetomidine CL (Rolle et al. 2018). 
Hepatic impairment and some other chronic illnesses may reduce albumin levels in 
plasma and this may exert significant effects on dexmedetomidine’s 
pharmacokinetics (Iirola et al. 2012, Lee et al. 2012, Välitalo et al. 2015). For 
example, an increased unbound fraction of dexmedetomidine in plasma may lead to 
prolonged effects as compared to healthy volunteers. 
The pharmacokinetics of dexmedetomidine in subjects with severe renal impairment 
(creatinine clearance < 30 ml/min) have not been found to be different relative to 
healthy subjects. When the pharmacokinetics of dexmedetomidine were compared 
in renally impaired patients and healthy volunteers, no differences were found in the 
volume of distribution or in the elimination CL (De Wolf et al. 2001, Zhong et al. 
2018). 
Critically ill patients 
Only limited information is available on the pharmacokinetics of long-term 
administration of dexmedetomidine in critically ill patients, and extensive inter-
individual variability has been described in an ICU population. In two studies 
assessing the population pharmacokinetics of dexmedetomidine infusions in 
critically ill ICU patients, age and body weight were found to be negatively 
associated with dexmedetomidine’s CL (Iirola et al. 2012, Välitalo et al. 2015). 
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Obese patients 
Many studies have found that body weight has an influence on the pharmacokinetics 
of dexmedetomidine (Välitalo et al. 2013, Hannivoort et al. 2015, Kuang et al. 2016). 
Cortinez et al (2015) compared the pharmacokinetics of intraoperatively 
administered dexmedetomidine in obese (BMI >35 kg/m2) and non-obese (BMI 
18.5–30 kg/m2) patients undergoing laparoscopic surgery. Patients received a 
loading dose of 0.5 µg/kg of dexmedetomidine followed by a constant-rate infusion 
of 0.25 to 0.5 µg/kg/h. A two-compartment pharmacokinetic model was employed, 
and fat free mass was found to the best covariate of dexmedetomidine’s 
pharmacokinetics (Cortinez et al. 2015). Based on reported pharmacokinetic studies, 
it appears that the body weight-adjusted dosing scheme that is currently applied is 
only reliable for non-obese patients; for obese patients, dosing should be based on 
fat-free mass. It has been claimed that if total body weight is used for weight-adjusted 
dosing of dexmedetomidine, it may lead to overdosing of obese subjects (Weerink 
et al. 2017). 
Pediatric patients 
There is rather limited information on the pharmacokinetics of dexmedetomidine in 
pediatric patients. In small children aged 2-20 months or 2-6 years, body weight-
adjusted plasma CL appeared to be larger (1.2 and 1.0 l/h/kg, respectively) than in 
adults (0.5-0.6 l/h/kg), but older children had an average CL that was comparable to 
adults (0.8 l/h/kg) (Potts et al. 2009, Hannivoort et al. 2015). In neonates aged < 2 
months, the plasma CL may be lower due to hepatic immaturity (Su et al. 2016). The 
elimination half-life of dexmedetomidine appears similar in children and in adults 
(Petroz et al. 2006, Diaz et al. 2007, Vilo et al. 2008).  
The pharmacokinetics of dexmedetomidine has been studied during more prolonged 
(45 - 223 h) infusions in critically ill children. Bayesian population modeling was 
employed to assess the drug concentrations measured during and after the infusions. 
It was found that the volume of distribution was increased 1.5-fold and clearance 
was increased 1.3-fold after termination of the infusion, once the concentration of 
dexmedetomidine had decreased to a level of approximately 1 ng/ml (Wiczling et al. 
2015). 
When the pharmacokinetics of intravenous dexmedetomidine infusions was studied 
in infants with postmenstrual age from 33 to 61 weeks, a younger postmenstrual age 
was a significant predictor of lower CL. For infants with postmenstrual age of 33 to 
61 weeks and body weight of 2 to 6 kg, the estimated CL and volume of distribution 
were 0.87 to 2.65 l/h/kg and 1.5 l/kg, respectively (Greenberg et al. 2017).  
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2.2.4  Pharmacokinetic interactions of dexmedetomidine 
Dexmedetomidine undergoes extensive biotransformation in the liver, this being 
partly mediated by cytochrome P450 enzymes. In vitro, dexmedetomidine has been 
found to inhibit some CYP enzymes (including CYP2B6) and to induce the activity 
of CYP1Α2, CYP2B6, CYP2C8, CYP2C9 and CYP3A4. There is potential for 
interaction between dexmedetomidine and substrates which undergo extensive 
metabolism by CYP2B6 (e.g. bupropion, artemisinin, pethidine, methadone) (Orion 
corp. 2018). Flexman et al. found that two enzyme-inducing anticonvulsant drugs, 
phenytoin and carbamazepine, increased the elimination clearance of 
dexmedetomidine on average by 43% (range, 10-100%) (Flexman et al. 2014). 
2.3  Pharmacodynamics of dexmedetomidine 
2.3.1  Sedative, amnestic and anesthetic sparing effect  
The α2A-adrenoceptor subtype has been shown to be the primary mediator of the 
sedative properties of α2-adrenoceptor agonists (Scheinin et al. 1994, Azure et al. 
2010). Dexmedetomidine causes fatigue by activating α2-adrenoceptors in the main 
noradrenergic cell body region of the brain, the locus coeruleus, which expresses 
α2A-adrenoceptors at a very high density (Wang et al. 1996). It affects the 
physiological state of vigilance by modulating the activity of GABA-ergic neurons 
of the pre-optic nucleus in the rostral hypothalamus as well as the activity of the 
descending medullospinal noradrenergic pathways. Hyperpolarization of 
noradrenergic neurons in the locus coeruleus suppresses noradrenaline release, 
leading to increased GABA and galanine activity in the tuberomamillary nucleus, 
which inhibits histamine secretion in cortical and subcortical projections (Figure 3) 
(Nelson et al. 2003). This results in hyperpolarization of spontaneously activated 
cells; this phenomenon is reflected as a naturally-occurring non-REM sleep pattern 
in electroencephalography (EEG) recordings (Guo et al. 1996, Huupponen et al. 
2008). 
The light level of sedation, good patient co-operability and many of the additional 
properties associated with the drug, such as analgesia, make dexmedetomidine an 
almost ideal sedative agent to be used in the ICU setting. Memory was preserved in 
healthy volunteers receiving dexmedetomidine with low target plasma 
concentrations (up to 0.7 ng/mL) of dexmedetomidine (Ebert et al. 2000), but some 
other studies have shown that dexmedetomidine may exert some amnestic effects 
(Hall et al. 2000, Venn et al. 2002). 
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Figure 3. Neural mechanisms of α2-adrenoceptor agonist-induced sedation. Wakefulness is 
promoted by the release of the arousal-promoting monoamine neurotransmitters, noradrenaline 
(NE), serotonin (5-HT), and histamine (His), from the locus coeruleus (LC), dorsal raphe nucleus 
(DR), and tuberomammillary nucleus (TMN), respectively, as well as acetylcholine (ACh) from the 
pedunculopontine and laterodorsal tegmental nuclei (PPTg and LDTg) and orexin (OX) from the 
perifornical area (PeF) into the cortex, forebrain, and subcortical areas. Conversely, during the 
deeper stages of non-REM sleep, the activity is reversed by the inhibitory action of GABA and 
galanin (Gal) released from the ventrolateral pre-optic nucleus (VLPO). Modified from Sanders and 
Maze, 2007. 
Clonidine was reported to reduce the minimal alveolar concentrations of inhalational 
anesthetics when used as an anesthetic adjunct (Inomata 2000). Similarly, 
dexmedetomidine lessened the need for intraoperative isoflurane (Aantaa et al. 1997) 
in adults and sevoflurane in pediatric patients (Savla et al. 2014). Intravenous 
dexmedetomidine infusions decreased the propofol concentrations required for 
sedation and suppression of motor responses (Dutta et al. 2001). The distribution of 
thiopental was reduced after dexmedetomidine administration; this was thought to 
be related to the decline in cardiac output and changes in regional blood flow. 
Similarly, dexmedetomidine reduced thiopental requirements to achieve EEG burst 
suppression (Bührer et al. 1994). 
2.3.2  Analgesic and opioid sparing effects 
The antinociceptive effects of α2-adrenoceptor agonists and the neuronal circuits 
involved have been extensively investigated. Analgesic effects of α2-adrenoceptor 
agonists are thought to occur both in the spinal cord and in the brain. In animal 
models, clonidine has been found to reduce the excitation caused by nociceptive 
stimuli in the dorsal root ganglia that are involved in the sensation of pain (Yagi et 
al. 1998, Wolff et al. 2007). It has been postulated that the activation α2C - and α2A-
adrenoceptors located in the dorsal horn of the spinal cord of rats by 
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dexmedetomidine suppressed pain transmission by reducing the release of the 
nociceptive transmitters, substance P and glutamate, and by hyperpolarization of 
interneurons (Ishii et al. 2008). In addition, clonidine has been found to prevent 
effectively the activation of hyperpolarization-activated cyclic nucleotide–gated 
channels in various types of nerve cells, such as neurons of the prefrontal cerebral 
cortex (Carr et al. 2007) and in dopaminergic nerve cells in the ventral tegmentum 
of the ventral forebrain (Inyushin et al. 2010).  
Animal studies have shown that α2-adrenoceptor agonists enhance opioid analgesic 
effects by prolonging the duration of analgesia and to a certain extent, by reducing 
the need for opioids to achieve analgesia (Meert et al. 1994). Opioids and 
dexmedetomidine have been found to display so-called isobolographic synergistic 
interactions. Dexmedetomidine has been reported to reduce the need for morphine 
and to lessen the development of chronic or neuropathic pain (Maze and Tranquili 
1991; Ossipov et al. 1989). In addition, dexmedetomidine has been demonstrated to 
exert neuroprotective effects in some animal models. There was a significant 
decrease in the extent of direct brain damage in the group of mice that received 
prophylactic dexmedetomidine before brain injury; this effect seemed to be mediated 
through the α2A-adrenoceptor subtype (Kingery et al. 2000). In another animal 
model, the combination of dexmedetomidine and lidocaine was found to reduce the 
emergence of ischemic brain injury (Goyagi et al. 2009). 
The analgesic effects of dexmedetomidine and clonidine have been widely 
investigated in humans. Clonidine has long been used as an adjuvant in neuraxial 
blockade, especially when the combination of an opioid and a local anesthetic does 
not produce adequate analgesia (Allen et al. 2018). Likewise, dexmedetomidine is 
known to decrease the need for local anesthetics when administered as an adjuvant 
into the intrathecal or epidural space. When 1 or 2 µg/kg of dexmedetomidine was 
administered to augment sacral block by bupivacaine in pediatric patients aged from 
1 to 6 years, the need for additional analgesics was significantly reduced in both 
dexmedetomidine groups as compared to patients receiving only bupivacaine (Al-
Zaben et al. 2015). In another study, sixty pediatric patients undergoing lower 
abdominal surgery received a single dose of epidural ropivacaine, with or without 
dexmedetomidine. In the dexmedetomidine group, the postoperative pain as well as 
the postoperative need for analgesics were significantly lessened for up to 18 hours 
after surgery (Kamal et al. 2016). 
Intravenous administration of dexmedetomidine has been found to decrease the need 
for postoperative opioids in patients undergoing surgery. In a double blind 
randomized controlled trial, patients undergoing total knee arthroplasty received 
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spinal anesthesia, and half of the patients were sedated with intravenous 
dexmedetomidine (approximately 1 µg/kg) in the procedure. Postoperative opioid 
consumption was significantly less in patients receiving dexmedetomidine for 
sedation. There was also a delay in the time to the first analgesic request (Chan et al. 
2016). In healthy volunteers, intravenous bolus doses of dexmedetomidine (0.25-1.0 
μg/kg) were found to be equally efficacious as intravenous fentanyl (2.0 μg/kg) in 
the treatment of ischemic limb pain (Jaakola et al. 1991). 
Preoperatively administered dexmedetomidine has been shown to reduce 
intraoperative and postoperative opioid consumption in patients undergoing surgery 
(Lawrence et al. 1997, Scheinin et al. 1993). Furthermore, systemically administered 
dexmedetomidine was reported to prolong the effect of intrathecal (Kaya et al. 2010) 
and plexus anesthesia (Rutkowska et al. 2009). In addition to its analgesic effect, 
when used as an intraoperative adjunct, dexmedetomidine was claimed to alleviate 
postoperative anxiety and to inhibit agitation in children (Patel et al. 2010). 
2.3.3  Effects on gastrointestinal functions 
When administered to laboratory animals and healthy volunteers, dexmedetomidine 
has been found to inhibit gastric emptying and gastrointestinal transit (Asai et al. 
1997, Iirola et al. 2011b). When healthy volunteers received 1 µg/kg of 
dexmedetomidine infused over 20 min followed by 0.7 µg/kg infusion for 190 min, 
it was found that dexmedetomidine quite markedly inhibited gastric emptying and 
prolonged gastrointestinal transit times. The effects were clearly more pronounced 
than those of the active comparator used in this trial, morphine (dosed 0.1 µg/kg 
intravenously) (Iirola et al. 2011b).  
On the other hand, dexmedetomidine has opioid sparing effects, which may help to 
reduce the constipation, nausea and vomiting caused by opioid drugs (Gertler et al. 
2001, Blaudszun et al. 2012). In some recent studies, dexmedetomidine has actually 
been shown to improve postoperative gastrointestinal motility in patients undergoing 
laparoscopic colonic resection (Chen et al. 2016, Wan et al. 2018). The clinical 
significance of the impact of dexmedetomidine on gastrointestinal functions is thus 
uncertain and may depend on individual patient characteristics. 
2.3.4  Effects on hemodynamics 
The two most evident effects of α2-adrenoceptor agonists on hemodynamics are 
bradycardia and hypotension. Clonidine, moxonidine and rilmenidine have been 
widely used for the treatment of essential hypertension. Upon intravenous 
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administration, the hemodynamic effects of dexmedetomidine and other α2-
adrenoceptor agonists have, however, been found to be biphasic. The sympatholytic 
effects induced by these drugs are mediated via the central nervous system, whereas 
activation of vascular α2-adrenoceptors mediates vasoconstriction and hypertensive 
effects (Figure 4). 
The hemodynamic effects of dexmedetomidine have been studied with various target 
concentrations in healthy volunteers. With high dexmedetomidine concentrations 
(i.e. > 3 ng/ml), HR decreased by up to 29% from baseline. Reductions in HR were 
seen until the plasma dexmedetomidine concentration was 3.2–5.1 ng/mL, after 
which a plateau was reached (Ebert et al. 2000). 
Talke et al. (2003) investigated dexmedetomidine-induced peripheral 
vasoconstriction in healthy volunteers. They found that low concentrations of 
dexmedetomidine in plasma induced vasodilation by reducing sympathetic tone, 
whereas high dexmedetomidine concentrations constricted blood vessels. The 
peripheral vasoconstrictive effects of low dexmedetomidine concentrations were 
more evident after pharmacological sympathectomy, i.e. brachial plexus block with 
a local anesthetic (Talke et al. 2003). 
The effects of dexmedetomidine on myocardial perfusion and cardiac function were 
assessed with positron emission tomography and transthoracic echocardiography. It 
was found that therapeutic plasma concentrations of dexmedetomidine clearly 
reduced myocardial blood flow, but plasma concentrations that significantly 
exceeded the recommended therapeutic level did not further attenuate myocardial 
perfusion nor did they induce any evident mismatch between cardiac oxygen demand 
and supply (Snapir et al. 2006). 
It has been stated that special caution should be exercised when treating patients with 
unstable hemodynamics, patients with bradycardia or atrioventricular block or 
patients receiving digoxin (Mason et al. 2010). Dexmedetomidine has been listed as 
a drug that may impair cardiac repolarization and prolong the QT interval in the 
ECG, although there are also studies suggesting that dexmedetomidine may actually 
shorten corrected QT interval (QTc) (Görges et al. 2015, Kako et al. 2015). 
In early animal studies, dexmedetomidine was found to reduce cerebral blood flow 
with no effect on the cerebral metabolic rate of oxygen, which raised concerns that 
the decreased blood flow might be inadequate for cerebral metabolic needs (Karlsson 
et al. 1990, Zornow et al. 1990). Farag et al (2017) compared regional brain 
oxygenation when patients were sedated with dexmedetomidine or propofol and 
observed that cerebral blood flow velocity was similarly preserved in both groups. 
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A recent study compared the effects of dexmedetomidine on the regional cerebral 
metabolic rate of glucose with three commonly used anesthetic drugs at equi-
sedative doses. Compared to propofol, sevoflurane and ketamine, the regional 
cerebral metabolic rate of glucose was lowest in the dexmedetomidine group 
(Laaksonen et al. 2018). These recent findings have alleviated concerns about 
dexmedetomidine-induced vasoconstriction and cerebral ischaemia. 
 
Figure 4. Integrative regulation of blood pressure by different α2-adrenoceptor subtypes. Modified 
from Philipp et al. 2002. 
2.3.5  Effects on respiration 
Respiratory depression is a well known and common side effect of many anesthetics 
and sedatives. Dexmedetomidine has been widely considered to be a sedative that 
does not impair respiration. The effect of dexmedetomidine infusion on respiration 
has been studied in spontaneously breathing volunteers. Dexmedetomidine at 
concentrations producing significant sedation reduced minute ventilation, but did not 
affect arterial oxygenation, arterial pH, or the slope of the carbon dioxide ventilatory 
response curve (Ebert et al. 2000). 
The effects of placebo, midazolam, propofol and dexmedetomidine on respiration 
have been compared in rabbits that had been anesthetized with sevoflurane. The 
apneic carbon dioxide thresholds of propofol and midazolam were larger than those 
of dexmedetomidine and placebo. The carbon dioxide sensitivity of the animals was 
somewhat reduced by dexmedetomidine as compared to placebo (Chang et al. 2009). 
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When dexmedetomidine was compared to propofol and midazolam in the sedation 
of ICU patients, it was found that dexmedetomidine was not inferior to midazolam 
and propofol in maintaining light to moderate sedation. Moreover, dexmedetomidine 
reduced the duration of mechanical ventilation in comparison with midazolam and 
improved the patients' ability to communicate about pain when compared with 
midazolam and propofol (Jakob et al. 2012). 
A recent study demonstrated that dexmedetomidine-induced sedation reduced 
ventilatory responses to hypoxia and hypercapnia to a similar extent as sedation with 
propofol. However, in that study, hypoxia was induced by lowering the inspired 
oxygen fraction (Lodenius et al. 2017). In an RCT of patients with obstructive sleep 
apnea, patients sedated with dexmedetomidine maintained upper airway patency 
better than patients sedated with propofol (Shin et al. 2018); nonetheless but it does 
seem that dexmedetomidine should be used with caution in patients with obstructive 
sleep apnea.  
Compared with other sedative agents, dexmedetomidine appears to be relatively safe 
with regard to respiration. However, dexmedetomidine is often administered 
concomitantly with other sedatives that have greater impacts on respiration, and 
dexmedetomidine may potentiate the respiratory depressant effects of these drugs. 
Therefore, caution is warranted when dexmedetomidine is used to treat patients at 
high risk for respiratory complications. 
2.3.6  Effects on renal function 
In animal studies, administration of dexmedetomidine has been shown to inhibit 
vasopressin secretion and to enhance diuresis already at low doses. It has been 
postulated that these actions may possibly protect the kidneys from ischemic insults 
(Villela et al. 2005). 
Diuresis-enhancing effects of dexmedetomidine have been reported also in humans, 
but the evidence is rather weak since the conclusions are based on only a few case 
reports (Ji et al. 2013, Pratt et al. 2013, Kirschen et al. 2019). 
2.3.7  Other effects - intraocular pressure, shivering, delirium, blood platelets 
α2-Adrenoceptor agonists (e.g. brimonidine) are used as eye drops to treat intraocular 
hypertension (Oh et al. 2018). It is well known that intubation increases intraocular 
pressure in anesthetized patients (Shribman et al. 1987) and therefore the effect of 
dexmedetomidine on intraocular pressure during intubation has been evaluated. It 
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has been shown that dexmedetomidine can lower intraocular pressure of intubated 
patients under general anesthesia (Zhou et al. 2017). 
Dexmedetomidine and clonidine are known to modulate thermoregulation, and their 
effects on postoperative shivering have been investigated (Horn et al. 1997, Pitoni et 
al. 2011). Postoperative shivering can evoke uncomfortable sensations that may 
trigger complications such as tachycardia, hypertension, and cardiac ischemia 
(Zhen-Xiu et al. 2015). Thus, attenuation of postoperative shivering could be a 
favourable way to reduce oxygen consumption. However, the hypothermia-
promoting effects of α2-adrenoceptor agonists need to be taken into account when 
treating patients with dexmedetomidine. It has been found that α2-adrenoceptor 
agonists are able to disturb thermoregulatory control mechanisms by lowering the 
thresholds for vasoconstriction and shivering without affecting the sweating 
threshold (Talke et al. 1997). In addition, many animal studies have demonstrated 
that α2-adrenoceptor agonists have hypothermic effects (Lähdesmaki et al. 2003, 
Gilsbach et al. 2009).  
Human blood platelets express α2A-adrenoceptors, and their activation enhances 
platelet aggregation (Lanza and Cazanave 1985). Kawamoto et al (2015) 
investigated the effects of dexmedetomidine on human platelets in vitro by using the 
somewhat non-selective α2-adrenoceptor antagonist, yohimbine, to block α2-
adrenoceptor activation. They found that dexmedetomidine had bidirectional effects 
on human platelet functions, i.e. enhancing aggregation through α2A-adrenoceptors 
but conversely exerting suppressive effects which were mediated via putative I1-
imidazoline receptors (Kawamoto et al. 2015). A recent study found that 
dexmedetomidine had no effects on human platelet function when this was evaluated 
with thromboelastography (Yoshikawa et al. 2018). Thus, the possible effects of 
dexmedetomidine on platelet aggregation in humans appear to be clinically 
insignificant. 
The effects of dexmedetomidine on the risk and occurrence of delirium have been 
investigated in ICU patients and in perioperative patient care. A recent meta-analysis 
showed that in comparison with traditional sedatives, dexmedetomidine reduced 
delirium and agitation in ICU patients (Ng et al. 2019). Postoperative administration 
of dexmedetomidine has also been claimed to reduce delirium in surgical patients, 
particularly following cardiac surgery (Pavone et al. 2018). The possible effects of 
intraoperatively administered dexmedetomidine on postoperative cognitive 
dysfunction were evaluated in elderly non-cardiac surgical patients, but the results 
were inconclusive (Zhang et al. 2018). 
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2.4  Dexmedetomidine in pediatric patients 
2.4.1  Pediatric ambulatory sedation 
Most pediatric patients undergoing surgical or other invasive procedures need 
sedation (Mahajan et al. 2014). Children are often frightened by the unfamiliar 
environment, strange people, and perhaps painful procedures, and do not understand 
why they are undergoing investigations or procedures and must remain confined. 
Even if many uncomfortable sensations and experiences can be attenuated with good 
personal care and the use of sedative and analgesic medications, all drugs have their 
own adverse effects and the pediatric anesthetist must be aware of these properties. 
Thus, there is a need for improving sedative regimens that provide comfortable 
experiences without any increased risk of complications (Hayden et al. 2016). 
GABAA receptor modulators such as propofol, midazolam and barbiturates are the 
traditional sedative agents that are used in ambulatory sedation of pediatric patients 
(Hansen 2015). All of these agents are highly amnestic and carry a risk of respiratory 
and cardiovascular depression. The amnestic properties of GABAA modulators may 
be favourable in ambulatory sedation but carry a risk for loss of cooperation and poor 
arousability. Ketamine is another traditional sedative agent that is used in sedation 
of pediatric subjects (Gyanesh et al. 2014). Its benefits over GABAA modulators 
include its minimal effects on respiration and hemodynamics. Moreover, ketamine 
is a relatively potent analgesic agent. Unfortunately, when used alone for sedation of 
pediatric patients, ketamine has been associated with the occurrence of 
hallucinations and nightmares and also with excessive salivation. Thus, it is 
recommended that ketamine should be used together with another sedative agent 
(e.g. midazolam) in order to reduce the risk of these side effects (Yang et al. 2019). 
In spite of the availability of many sedative agents that can be used safely and 
efficiently in the ambulatory sedation of pediatric patients, a single optimal sedative 
agent is still lacking.  
2.4.2  Use of dexmedetomidine in children 
Dexmedetomidine has marketing authorization only for adult patients and the use 
of dexmedetomidine in pediatric patients is off-label. Dexmedetomidine appears to 
have many favourable properties for use as a pediatric sedative agent, such as the 
fact that it exerts only marginal effects on respiration. In fact, it has been widely 
used in pediatric intensive care, as an anesthetic adjunct and as premedication 
(Tobias and Berkenbosch 2008, Mason and Lerman 2011).  
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The use of dexmedetomidine in the ambulatory sedation of pediatric patients is rather 
common, particularly in the sedation of children undergoing magnetic resonance 
imaging (MRI). Conventional MRI sedation of pediatric patients has been attempted 
with propofol, barbiturates, benzodiazepines, chloral hydrate, ketamine, remifentanil 
or sevoflurane; most of these compounds may cause respiratory depression or 
hypotension, which in extreme cases can be harmful to the child (Starkey et al. 2011, 
Hansen et al. 2015, Pedersen et al. 2013). An ideal sedation protocol should have 
minimal effects on respiration and hemodynamics, keep the child calm and immobile 
during the procedure, but allow rapid recovery and discharge. While 
dexmedetomidine may possess many of these favourable properties, its optimal 
dosage for MRI sedation still remains unknown. 
Various dose regimens of dexmedetomidine have been employed in pediatric patients. 
Recommended adult doses vary from 0.5 to 1.4 µg/kg. In children, intravenous doses 
are typically higher, even up to 2.5 µg/kg. Recent reports indicate that very high doses 
of dexmedetomidine (up to 9 µg/kg intravenously delivered over 30 min) can be safely 
administered to children aged 2 to 6 years (Mason et al. 2010). On the other hand, the 
cardiac output of neonates and infants is highly dependent on HR (Winberg et al. 
1992). Thus, the hemodynamic effects of dexmedetomidine should be taken account 
and closely monitored when administering the drug to children. 
The effects of dexmedetomidine infusions lasting over three days have been studied 
in critically ill pediatric patients. After addition of dexmedetomidine to the treatment, 
patients were more comfortable as evidenced by decreasing Comfort-B scores 
(CBSS). The hemodynamic effects of dexmedetomidine did not limit its long-term 
use, but withdrawal from dexmedetomidine was, however, associated with agitation, 
tremors, and decreased sleep (Whalen et al. 2014). There is also some experience of 
the use of dexmedetomidine in critically ill neonates and infants. It has been 
recommended that administration of dexmedetomidine in these patients should be 
very cautious because of their potentially inadequate capacity of glucuronidation and 
poorly developed drug metabolism. Thus, especially in newborns, the drug dosage 
may have to be lower than in older children and adults (Estkowski et al. 2015).  
2.5  Extravascular administration of dexmedetomidine 
2.5.1  Introduction to extravascular administration 
Although dexmedetomidine is only registered for intravenous use, multiple 
alternative routes of administration have been investigated. The rationales for 
extravascular administration include ease of administration in certain patient 
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populations and clinical settings and the possibility to avoid the high peak plasma 
levels encountered after intravenous administration. Another advantage of 
extravascular administration is the lack of need for intravenous access. This can 
improve patient satisfaction e.g. in the pediatric patient population. 
The examples given below show that regardless of the route of administration, 
similar adverse effects may occur as are present after intravenous administration. 
However, these effects are likely to be attenuated in comparison with intravenous 
administration. 
2.5.2  Intranasal administration 
Of the different extravascular routes of administration of dexmedetomidine that have 
been investigated, the intranasal route appears to be the most popular and feasible. 
There are some systematic reviews on the effects of intranasal dexmedetomidine in 
children, but only three small pharmacokinetic studies have been published 
describing intranasal administration of dexmedetomidine in children and adults. 
In the study of Iirola et al (2011), six healthy male adult volunteers received 84 µg 
of intranasal and 84 µg of intravenous dexmedetomidine. Systemic bioavailability 
of the intranasal spray formulation was variable, ranging from 35% to 93% in the 
individual subjects, with a mean bioavailability of 65%. Heart rate was significantly 
lower during the initial 0- to 30-min period after intravenous administration in 
comparison to the corresponding situation when the drug was delivered intranasally, 
but there was no statistically significant difference over the 0- to 10-h period. 
Systolic and diastolic blood pressures were similar regardless of the administration 
route (Iirola et al. 2011a). 
Li et al. (2018) compared approximately 1 μg/kg doses of dexmedetomidine 
administered either as intranasal drops or with an intranasal atomizer as well as the 
same dose intravenously during three separate sessions in eight healthy adult 
volunteers. The mean bioavailability of intranasal dexmedetomidine was found to be 
41 to 65%. The onsets of effects were at 15, 48 and 60 min after intravenous dosing, 
intranasal spray and intranasal drops, respectively. There were no significant 
differences in the duration of sedation (Li et al. 2018). 
Miller et al. (2018) evaluated the pharmacokinetics of intranasally delivered 
dexmedetomidine in pediatric patients (age 6-44 mo) undergoing cardiopulmonary 
bypass. Six patients received 1 μg/kg and six patients received 2 μg/kg of intranasal 
dexmedetomidine, and another six patients received 1 μg/kg of intravenous 
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dexmedetomidine. Median peak concentrations of dexmedetomidine were 0.2 and 
0.36 ng/ml and median times to peak concentration were 47 minutes and 46 minutes 
after the two different intranasal dosages. The relative bioavailability of intranasal 
dexmedetomidine appeared to be 84% (Miller et al. 2018). 
2.5.3  Intramuscular administration 
Intramuscularly administered dexmedetomidine appears to have good bioavailability 
and may be used when the drug is to be given as a single dose. Scheinin et al. (1992) 
compared single intramuscular doses of dexmedetomidine (0.5, 1.0, and 1.5 µg/kg) 
to placebo in six healthy subjects in a single-blind crossover study. A linear one-
compartment open model was used to calculate pharmacokinetic parameters. 
Compared to placebo, up to 22% decreases in systolic and diastolic blood pressure 
were seen, with maximal effects observed between 90 and 150 minutes after drug 
administration. There was no clear dose dependency of the hypotensive effect, with 
the 1.0 and 1.5 µg/kg doses having rather similar effects (Scheinin et al. 1992). 
In a randomized, controlled multi-center study, single doses of intramuscular 
dexmedetomidine were administered to ASA 1-2 patients undergoing elective 
abdominal hysterectomy, cholecystectomy or intraocular surgery. Pretreatment with 
a single intramuscular injection of 2.5 µg/kg dexmedetomidine induced comparable 
sedation and anxiolysis as an intramuscular injection of 0.08 mg/kg midazolam. 
Compared to midazolam, patients receiving dexmedetomidine for premedication 
required 56% less fentanyl intraoperatively. The use of dexmedetomidine as a 
premedication increased the incidence of intraoperative hypotension and bradycardia 
(Scheinin et al. 1993). 
Intravenous and intramuscular administration of dexmedetomidine has been examined 
in healthy male volunteers with ten subjects receiving 2.0 µg/kg via both routes. Five 
minutes after intravenous dosing, there was a 22% mean increase in MAP and a 27% 
mean decrease in HR. These kinds of early hemodynamic effects were not seen after 
intramuscular administration. During the 4 h follow-up after the intramuscular dose, 
MAP decreased by 20% and HR was reduced by 10% (Dyck et al. 1993a). 
In the trial conducted by Anttila et al. (2003), 2.0 µg/kg doses of dexmedetomidine 
were given intravenously, intramuscularly, per orally and buccally to 12 healthy 
male subjects. Compared to intravenous administration, intramuscular injection 
appeared to have complete bioavailability, with relative AUC values in the range of 
96–112%. Hemodynamic or other effects were not described in that study report 
(Anttila et al. 2003). 
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2.5.4  Buccal and oral administration 
In the above-mentioned study of Anttila et al. (2003), oral administration of 2.0 
µg/kg doses of dexmedetomidine displayed poor bioavailability in a range of 12-
20%, but buccally administered doses were well absorbed, with the dose-corrected 
bioavailability in a range of 73–92%. (Anttila et al. 2003). 
2.5.5  Other routes of administration 
The use of subcutaneous administration of dexmedetomidine in humans has earlier 
been reported in only one case report, where dexmedetomidine was administered 
subcutaneously in the palliative care of a dying adult patient (Hilliard et al. 2015). 
Kivistö et al. (1994) compared the pharmacokinetics of transdermally and 
intravenously administered dexmedetomidine in healthy volunteers. The transdermal 
preparation, containing 625 µg of dexmedetomidine base, was applied to the skin for 
12 h. The intravenous dose (2.0 µg/kg as dexmedetomidine hydrochloride) was 
administered as an infusion over 5 min. The mean relative systemic bioavailability of 
dexmedetomidine from the transdermal preparation was 51%, but the proportion of 
dexmedetomidine released from the preparation was 88%. The mean terminal half-life 
was 3.1 h after intravenous dosing and 5.6 h after transdermal administration. With the 
transdermal administration, the mean maximal reductions in blood pressure 
(systolic/diastolic) and HR were 28/20 mmHg, and 19 bpm. Sedative effects were 
observed 1-2 h after the start of transdermal administration (Kivistö et al. 1994). 
Zanaty et al. (2015) compared the pharmacodynamics of inhaled nebulized 
dexmedetomidine (2 µg/kg), nebulized ketamine (2 mg/kg) and their combination (1 
µg/kg and 1 mg/kg) in children undergoing dental surgery. Sedative effects were 
recorded 30 min after administration of nebulized dexmedetomidine with the most 
satisfactory sedation being observed after administration of the 
dexmedetomidine/ketamine combination (Zanaty et al. 2015). 
2.6  Pharmacometric modeling of dexmedetomidine 
2.6.1  Introduction to pharmacometric modeling 
Understanding of dose–concentration–effect relationships is a fundamental 
component of clinical pharmacology. In traditional pharmacokinetic studies, a 
sufficient number of samples must be collected to allow a reliable pharmacokinetic 
analysis to be performed on an individual subject basis, irrespective of whether that 
analysis is a simple computation of non-compartmental parameters or a more 
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sophisticated estimation of the parameters of a pharmacokinetic model through 
nonlinear regression or other numerical analysis techniques (Standing et al. 2017). 
Data are considered “sparse” when an insufficient number of samples have been 
collected in an individual to allow relevant pharmacokinetic analysis to be performed 
for that individual (Owen and Fielder-Kelly 2014). 
The traditional method of pharmacokinetic data analysis uses a two-stage approach. 
The first stage involves an estimation of the pharmacokinetic parameters by 
conducting a nonlinear regression using the individual's drug concentration-time 
data. Individual parameter estimates obtained during the first stage serve as input for 
the second-stage calculation of descriptive summary statistics on the sample, 
typically, mean parameter estimates, variance and covariance of the individual 
parameter estimates (Mould et al. 2013). This method encounters inherent problems 
due to errors in dosing compliance, missing samples, and other data errors that are 
present, resulting in biased parameter estimates. Therefore, this two-stage approach 
is no longer in use; nonetheless many earlier studies have employed it and these 
deficiencies should be taken into account when interpreting previous results. 
Population pharmacokinetic-phamacodynamic methodology involves the 
application of the concepts of non-linear mixed effects modeling to model 
unexplained inter- and intra-individual variability (Mould and Upton, 2012). A 
mixed-effects model is a statistical model that incorporates both fixed effects and 
random effects. Fixed effects are population parameters assumed to be the same each 
time when data are collected, and random effects are random variables associated 
with each sample (individual) from a population. Mixed-effects models can be 
developed with small sample sizes and sparse data sets, and are often used to draw 
inferences on features underlying profiles of repeated measurements from a group 
of individuals from a population of interest (Mould et al. 2013). 
Pharmacometric models account for the general structure of the underlying system, 
and a set of hierarchical variability components between subjects, within subjects 
over time and between observation variability (Mould and Upton, 2013; Upton and 
Mould, 2014). The analysis of pharmacokinetic and pharmacodynamic data includes 
mathematical models of pharmacology, disease, biology and physiology for 
describing and quantifying interactions, both beneficial and deleterious, between 
xenobiotics and patients (Barrett et al. 2008). Pharmacometric approaches are further 
used to elucidate the effects of covariates. This results in the creation of models 
which can be used in simulations that make inferences on optimum dosing for 
clinical practice (Standing et al. 2017). 
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The general model strategy is first to develop a structural model that explains the 
population trend in the dose-concentration-effect relationship. Previous knowledge 
about the drug substance and on human physiology is used to build a structural 
model. Then, a statistical model is developed and incorporated into the structural 
model to explain the between-subject and residual variability in the data. Finally, the 
influence of observable patient characteristics (covariates) such as body weight and 
age on the different model parameters are explored and incorporated into the model 
as predictors of clinical relevance. The predictive capability of the final model is 
assessed by visualizing the correlation between observations and model predictions 
using graphical analysis. The biological plausibility of the parameter estimates and 
their uncertainty are assessed by using simulation-based diagnostics, such as 
bootstrap or sampling-importance-resampling procedures (Owen and Fielder Kelly 
2014). 
Frequently obtained samples and observations from actual patients compatible with 
clinical care can be used instead of designing a specific experimental setting which 
minimises the burden for each individual subject. Importantly, the obtained 
information may often be directly applied into clinical practice (Vermeulen et al. 
2017). It has been stated that pharmacometric models should be employed in model-
informed precision dosing (MIPD) to improve drug therapy by estimating the 
optimal dose for an individual patient. MIPD aims to improve therapeutic outcomes 
in patients by searching for the optimal balance between efficacy and toxicity. The 
approach is based on the available information about the patient, the disease for 
which they are treated, the presence of comorbid diseases, and the drug therapies 
they are receiving. MIPD is inclusive of various modeling approaches including 
pharmacometrics. 
2.6.2  Pharmacokinetic models of dexmedetomidine 
Several pharmacokinetic models have been developed for dexmedetomidine. In most 
studies, a two-compartment pharmacokinetic model with zero order input to and 
linear elimination from the central compartment has been used to describe 
dexmedetomidine disposition and elimination, whereas four studies found a three-
compartment pharmacokinetic model to be more appropriate (Dyck et al. 1993b, 
Dutta et al. 2000, Lin et al. 2011, Hannivoort et al. 2015, Kuang et al. 2016). Two 
studies employed one-compartment models to describe the pharmacokinetics of 
dexmedetomidine (Välitalo et al 2015, Greenberg et al. 2017). An overview of 
published population-based pharmacokinetic dexmedetomidine models in adult and 
pediatric populations is presented in Tables 3 and 4. 
Table 3. Overview of published population pharmacokinetic dexmedetomidine models in the adult population. 
Study (year) N Patient population 
No. of 
samples 
Last 
sample 
(h) 
Dexmedetomidine 
administration Tested Covariates Covariate models 
Dyck 1993 16 Male healthy volunteers 14 2 IV TCI Age, weight, height 3 -CMT with height as a covariate on CL 
Talke 1997 8 Female postoperative patients 8 3 IV TCI Age, weight, height 
2-CMT with no relationship 
between covariates 
Dutta 2000 10 Healthy male volunteers 10 4 IV TCI CO 2-CMT with CO as covariate on CL 
Venn 2002 10 Postoperative ICU patients 10 12 
IV infusion with a 
loading dose None 
2-CMT with no tested 
covariates reported 
Lin 2011 22 Chinese postoperative patients 24 12 
IV infusion with a 
loading dose 
Age, weight, height, 
sex, BMI, LBM 
3-CMT with height as a 
covariate on CL 
Iirola 2012 21 Critically ill patients 11 100-550 
IV infusion with a 
loading dose 
Age, weight, height, 
sex, BMI, LBM 
2-CMT with age as a covariate 
on CL and ALB on V2 
Lee 2012 24 Korean healthy volunteers 13 12 IV infusion with a loading dose 
Age, weight, serum 
creatinine, LT, 
albumine 
2-CMT with ALB as a covariate 
on CL and age on V1 
Välitalo 2013 527 Critically ill patients 2-3 48 IV infusion with a loading dose 
Age, weight, CC, 
bilirubin, LT, ALB 
1-CMT with weight as a 
covariate on CL and ALB on V1 
Cortinez 2015 40 
Obese and non-obese 
laparoscopic surgery 
patients 
21 6 IV infusion with a loading dose 
Age, weight, fat free 
mass, normal fat 
mass 
2 CMT with FFM as a covariate 
on CL, Q2, V1 and V2,  
Hannivoort 2015 18 Healthy volunteers 14 5 IV TCI Age, weight, height, BMI, sex 
3-CMT with a weight as a 
covariate on CL, Q2, Q3, V1, 
V2 and V3 
Kuang 2016 35 
Chinese patients 
undergoing spinal 
anesthesia 
15 10 IV infusion with a loading dose 
Age, weight, height, 
sex, BMI, LT, CC 
3-CMT with ALT as a covariate 
on CL, age on V1 and weight 
on V2 
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 Study (year) N Patient population 
No. of 
samples 
Last 
sample 
(h) 
Dexmedetomidine 
administration Tested Covariates Covariate models 
Zhong 2018 23 
Patients with normal renal 
function and patients with 
end-stage renal disease 
13 8 IV infusion 
Age, weight, height, 
sex, BMI, LBM, BSA, 
ALB, renal function 
2-CMT with no relationship 
between covariates 
Smuszkiewicz 
2018 27 Critically ill patients 14 24-102 IV infusion 
Age, weight, sex, 
SOFA, infusion 
duration, use of 
inotropes 
2-CMT with no relationship 
between covariates 
Rolle 2018 40 
Obese and non-obese 
patients undergoing 
laparoscopic surgery 
18 12-20 IV infusion with a loading dose 
weight, LBM, ABW, 
hepatic blood flow, 
liver steatosis, ALT 
2-CMT with hepatic blood flow 
as a covariate on CL 
ABW; adjusted body weight, ALB; serum albumine, ALT; alanine transaminase, AST; aspartate transaminase,  BSA; body surface area, CC; creatinine clearance, CL; 
clearance, CMT; compartment model, CO; cardiac output, IV; intravenous, LBM; lean body mass, SOFA; sequential organ failure assessment score TCI; target controlled 
infusion 
*Modified from Weerink et al. 2017 
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 Table 4. Overview of published population pharmacokinetic dexmedetomidine models in the pediatric population. 
Study (year) N 
Patient 
population 
No. of 
samples 
Last 
sample 
(h) 
Dexmedetomidine 
administration Tested Covariates Covariate models 
Potts 2009 95 Pediatric ICU patients 4 8 
IV infusion with a 
loading dose 
Age, weight, cardiac 
surgery, 
arterial/venous 
sampling, study site 
2-CMT with age, weight and postcardiac 
surgery state as covariates on CL and 
weight as a covariate on Q2, V1 and V2 
Su 2010 36 
Pediatric 
cardiac 
postoperative 
patients 
13 24 IV infusion with a loading dose 
Age, weight, 
cardiopulmonary 
bypass time, 
ventricular 
physiology 
2-CMT with age and ventricular 
physiology as covariates on CL 
Liu 2016 39 
Pediatric 
general surgery 
patients 
13 8 IV infusion Age, weight, BMI, sex, LBM 
2-CMT with weight as a covariate on CL, 
Q2, V1 and V2 
Su 2016 59 
Neonatal and 
pediatric 
postoperative 
patients 
6-14 18 IV infusion with a loading dose 
Age, weight, total 
cardiopulmonary 
bypass time, 
ventricular 
physiology 
2-CMT with age, weight, total bypass 
time and ventricular physiology as 
covariates on CL and weight as a 
covariate on Q2, V1 and V2 
Wiczling 2016 38 
Critically ill 
pediatric 
patients 
15 6 IV infusion 
Age, weight, cardiac 
surgery, 
arterial/venous 
sampling, study site 
2-CMT with age and weight as a 
covariate on CL and weight on Q2, V1 
and V2 
Greenberg 2017 20 Pre-term and term infants 5-10 
250-
1500 IV infusion Age, weight 
1-CMT with age and weight as a 
covariate on CL and weight on Vd 
Perez-Guille 
2018 30 
Ambulatory 
pediatric 
patients 
14 10 IV infusion Age, weight 2-CMT with weight as a covariate on CL 
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 Study (year) N 
Patient 
population 
No. of 
samples 
Last 
sample 
(h) 
Dexmedetomidine 
administration Tested Covariates Covariate models 
Damian 2018 20 
Children and 
infants 
undergoing liver 
transplantation 
20 72 IV infusion with a loading dose 
Age, weight, liver 
ischemia time, donor 
age, liver type, INR, 
bilirubin, ALT, AST 
2-CMT with weight as a covariate on CL 
Miller 2018 18 
Pediatric 
patients 
undergoing 
cardiopulmonar
y bypass 
8 2 IV 10 min bolus or intranasal bolus Age, weight 2-CMT with weight as a covariate on CL 
ALB; serum albumine, ALT; alanine transaminase, AST; aspartate transaminase, BSA; body surface area, CL; clearance, CMT; compartment model, CO; cardiac output, 
INR; international normalized ratio, IV; intravenous, LBM; lean body mass 
*Modified from Weerink et al. 2017 
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2.6.3  PK/PD models of dexmedetomidine 
Very few models have described dexmedetomidine PK/PD relationships. Yoo et al. 
(2015) developed a mechanism-based population PK/PD model for the 
cardiovascular and central nervous system effects of intravenously and intranasally 
administered dexmedetomidine in healthy subjects. The comprehensive panel of two 
biomarkers and seven response measures were well captured by the population 
PK/PD models. The subjects were more sensitive to the central nervous system 
effects (smaller EC50 values) than to the cardiovascular effects of dexmedetomidine 
(Yoo et al. 2015). 
Colin et al. (2017a, 2017b) published two models based on an earlier PK model.  
Dexmedetomidine was given to healthy volunteers using the model published by 
Dyck et al. (1993) with different dexmedetomidine target concentrations and two 
PK/PD models were created without blood sampling. The first model described 
dexmedetomidine-induced hypotension, hypertension and bradycardia, whereas the 
second described the sedative properties of dexmedetomidine utilizing the bispectral 
index and a Modified Observer´s Assessment of Alertness/Sedation (Colin et al. 
2017a, Colin et al 2017b). 
Li et al. (2018) conducted a PK/PD analysis of intravenously and intranasally 
administered dexmedetomidine in eight healthy human volunteers on three separate 
sessions. A two-compartment disposition model was used in the pharmacokinetic 
analysis, and the effect of dexmedetomidine on sedation was modelled with a 
sigmoidal Emax model driven by an effect compartment. The effect compartment had 
an equilibration half-time of 3.3 min and the EC50 in plasma was estimated to be 903 
pg/ml (Li et al. 2018). 
Recently, the peripheral vasoconstrictive effect of dexmedetomidine was evaluated. 
Dexmedetomidine was administered as intravenous target-controlled infusion (TCI) 
to ten healthy volunteers and arterial blood samples were collected for analysis of 
plasma dexmedetomidine concentration. Sympathetic nerve fibers were blocked 
unilaterally with a brachial plexus block and peripheral vasoconstrictive effects of 
dexmedetomidine were assessed using photoelectric plethysmography (Talke et al. 
2018). An overview of the PK/PD models of dexmedetomidine is presented in Table 
5. 
 
Table 5. Overview of published dexmedetomidine PK/PD models in the adult population. 
Study (year) N Patient 
population 
No. of 
samples 
Last 
sample (h) 
Dexmedetomidine 
administration 
Model properties 
Yoo 2015 6 Healthy volunteers 15 10 
IV 10 min bolus or 
intranasal bolus 
2-CMT with Emax model for noradrenaline release 
and hemodynamic effects 
Colin 2017 35 Healthy volunteers 0** - IV TCI 
Emax model for bispectral index and Modified 
Observer's Assessment of Alertness/Sedation 
Colin 2017 23 Healthy volunteers 0** - IV TCI 
Emax model for mean arterial pressure and heart 
rate 
Li 2018 8* Healthy volunteers 12 8  
IV 10 min bolus, IN 
spray, IN drops 
2-CMT with Emax model for Ramsey sedation 
score 
Talke 2018 10 Healthy volunteers 14 1,25 IV TCI 3-CMT with Emax model for vasoconstriction 
ALB; serum albumin, ALT; alanine transaminase, AST; aspartate transaminase, BSA; body surface area, CC; creatinine clearance, CL; clearance, CM; compartment model, 
CO; cardiac output, Emax; maximal effect of dexmedetomidine, IV; intravenous, LBM; lean body mass, TCI; target controlled infusion 
*On three separate sessions, ** pharmacokinetic model was based on TCI target concentrations 
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III  AIMS OF THE STUDY 
The present series of clinical investigations was conducted with the overall aim to 
acquire an improved understanding of the alternative, extravascular routes of 
administration of dexmedetomidine and of the pharmacokinetics and 
pharmacological effects of dexmedetomidine in pediatric patients. Specifically, the 
individual aims of the different sub-projects were as follows:  
1. To determine the pharmacokinetics of subcutaneously administered 
dexmedetomidine in healthy adult volunteers. 
2. To build a PK/PD model of subcutaneously administered dexmedetomidine 
in healthy adult volunteers. 
3. To clarify the pharmacokinetics and effects of intranasally delivered 
dexmedetomidine in pediatric patients undergoing MRI imaging. 
4. To evaluate the barbiturate-sparing effect of intranasally administered 
dexmedetomidine in pediatric patients undergoing MRI imaging. 
5. To examine whether intranasal low-dose dexmedetomidine possesses 
postoperative opioid-sparing properties in adult surgical patients.  
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IV  MATERIALS AND METHODS 
4.1  Subjects 
4.1.1  Study participants 
Altogether 10 healthy male volunteers, 255 pediatric patients and 120 adult patients 
participated in Studies I, II-III and IV, respectively. The number of subjects and their 
demographics are presented in Table 6. 
Table 6. Characteristics of the subjects in studies I-IV and subsequent publications. 
 Study I Study II Study III Study IV 
 Study Ia Study Ib    
Name of the study SCDEX SCDEXMOD PINDEX TIODEX PROTEDEX 
Number of 
participants 
8 10 55 200 120 
Study design Prospective Prospective Prospective Retrospective Retrospective 
Dexmedetomidine 
dose 
1 µg/kg 1 µg/kg 2-3 µg/kg 3 µg/kg 0.5-1.0 µg/kg 
Administration route IV, SC IV, SC IN IN IN 
Age (yr) 23.0 (2.3) 22.6 (2.2) 5.0 (2.4) 4.5 (2.6) 67 (9.0) 
BMI (kg/m2) 24.2 (1.6) 23.9 (1.5) 16.3 (2.2) 16.5 (2.2) 27.5 (3.6) 
Weight (kg) 78.4 (6.9) 79.9 (7.1) 19.9 (6.9) 18.8 (7.5) 78.4 (12.0) 
Publication I II III IV V 
Age, height and weight are expressed as mean and SD. IV; intravenous, SC; subcutaneous, IN; intranasal, 
BMI; body mass index 
4.1.2  Inclusion and exclusion criteria 
In Study I, healthy, non-smoking male volunteers aged between 18 and 30 years 
were recruited via internet advertisements directed to university students. After 
obtaining written informed consent, subject eligibility was evaluated by examining 
their medical history and a physical examination as well as laboratory screening 
tests. 
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In Studies II and III, pediatric patients aged between 1 month and 11 years were 
included if they had normal developmental status and were scheduled for MRI 
requiring sedation or anesthesia at Turku University Hospital. In Study II, informed 
consent was obtained from all guardians and patients (if relevant).  
In Study IV, one hundred and twenty patients with ASA status 1-2, age between 35 
and 80 years, weight between 50 and 100 kg and scheduled for primary unilateral 
hip arthroplasty under total intravenous anesthesia were included. According to 
Finnish law and Ethics committee of South-West Finland Hospital District Studies 
III and IV did not require consent from patients to participate. 
4.1.3  Exclusion criteria of studies I-IV 
Exclusion criteria of all studies included existing or recent significant disease that 
could influence the study outcome or cause a health hazard for the subject during the 
study, clinically significant abnormal findings in physical examination or laboratory 
screening, previous history of intolerance to the study drug or to related compounds 
and additives, prior drug therapy with dexmedetomidine in the 14 days prior to the 
study, use of any drugs (e.g. CYP inducers or inhibitors) known to cause enzyme 
induction or inhibition for a period of 30 days prior to the study and participation in 
any other clinical study involving investigational or marketed drug products 
concomitantly or within one month prior to the entry into this study. Patients 
receiving any medications other than paracetamol or adjuvant analgesics that could 
affect the study outcome were further excluded from studies I and IV.  
4.2  Study designs 
4.2.1 Pharmacokinetic studies (I-II) 
Study I was an open two period study with a cross-over design and balanced 
randomization. The wash-out period between consecutive administrations was at 
least 3 weeks. Eleven volunteer subjects compatible with the inclusion and exclusion 
criteria were entered into the study after informed consent. Figure 5 illustrates the 
study schedule. 
Study II was an open prospective one period study. Patients potentially eligible for 
the study were approached for information, preliminary assessment of eligibility 
criteria and consent either during their preoperative visit or upon arrival at the 
hospital for the procedure. Written informed consent was obtained from the patients 
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(if applicable) and their guardians before any study-specific procedures were carried 
out. Figure 5 illustrates the study procedures. 
     
Figure 5. Study setting of the study I (left) and study II (right). 
4.2.2  Pharmacodynamic studies (III-IV) 
In Studies III and IV, eligible patients were identified and patient data were retrieved 
from the anesthesia reports and the patient database of the hospital. Study III was a 
comparative retrospective study, where 200 pediatric patients undergoing MRI were 
examined. Half of the patients were consecutive pediatric patients receiving 3 µg/kg 
of intranasal dexmedetomidine 45-60 min before the MRI procedure while the rest 
were 100 consecutive patients receiving only thiopental for MRI sedation. Sedation 
was maintained with intravenous thiopental when applicable. Thiopental 
consumption was analyzed for both groups.  
Study IV was a comparative retrospective study, where 120 patients undergoing 
unilateral hip arthroplasty under general anesthesia were included. Half of the 
patients were consecutive patients receiving 50 µg of intranasal dexmedetomidine 
after anesthesia induction; the others were 60 consecutive patients receiving 
conventional general anesthesia without dexmedetomidine. HR and MAP were 
recorded continuously during the operation and in the PACU. Postoperative opioid 
consumption was analyzed for both groups. 
Day 1 Screening 
 Informed consent 
Medical history 
 Physical examination 
 Laboratory screening 
Day 2 Study session I 
Dexmedetomidine either 
intravenously or subcutaneously 
Wash-out period of at least 3 
weeks 
Day 3 Study session II 
Dexmedetomidine either 
intravenously or subcutaneously 
Day 1 Screening 
Medical history 
Physical examination if 
applicable 
Laboratory screening if 
applicable 
Day 2 Study session I 
Informed consent  
Dexmedetomidine intranasally 
Follow up 
Discharge according to local 
criteria 
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4.3  Dexmedetomidine dosing 
In Study I, healthy volunteers were scheduled to receive 1 µg/kg of 
dexmedetomidine intravenously and subcutaneously in a randomized order. 
Intravenous and subcutaneous doses of dexmedetomidine were administered at 
concentrations of 8 µg/ml and 50 µg/ml during 10 min by infusion with the same 
pump. There were no prior studies on subcutaneous administration of 
dexmedetomidine, but the dosage used in our study was based on similar studies 
where dexmedetomidine had been administered intramuscularly or intranasally 
(Scheinin et al 1992, Iirola et al. 2011a). 
In Studies II and III, pediatric patients received 2-3 µg/kg doses of dexmedetomidine 
intranasally 45-60 min before the scheduled MRI procedure. Dexmedetomidine 
(Dexdor®100 µg/ml, Orion Pharma, Espoo, Finland) was administered intranasally 
in the semi-recumbent position using a LMA MAD NasalTM device (Teleflex MAD 
Nasal, NC, USA) (Figure 6). The dexmedetomidine dosage used in this study was 
based on previous reports (Mason et al. 2008, Siddappa et al. 2011, Mason et al. 
2010) which had determined the safety of dexmedetomidine at doses up to 9 μg/kg 
given intravenously over 30 min. 
In Study IV, adult patients undergoing hip arthroplasty under general anesthesia 
were scheduled to receive 50 µg of dexmedetomidine intranasally after anesthesia 
induction. Intranasal dexmedetomidine was administered in the supine position with 
the MAD device. Dexmedetomidine dosage was according to a local protocol based 
on previous reports (Xu et al. 2014) which had confirmed the safety of 
dexmedetomidine at doses up to 1 μg/kg given intravenously over 10 min to patients 
undergoing hip arthroplasty. 
  
Figure 6. MAD nasal spray device. 
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4.4  Blood sampling and analysis of dexmedetomidine and 
catecholamine concentrations 
4.4.1  Blood sampling 
Blood samples for plasma dexmedetomidine and/or catecholamine analysis were 
drawn in Studies I and II. In Study I, arterial blood samples (blood volume 5 ml) 
were collected immediately prior to administration of dexmedetomidine (baseline) 
and thereafter at 5, 10, 15, 20, 30, 45 min and 1, 1.5, 2 and 3 h into EDTA tubes for 
the determination of concentrations of dexmedetomidine, adrenaline and 
noradrenaline in plasma. Further blood samples were collected at 4, 5, 6, 8 and 10 h 
after dexmedetomidine administration for the determination of dexmedetomidine. 
In Study II, venous blood samples (blood volume 1 ml) were collected during the 
assumed absorption phase, i.e. 10 and 20 min after drug administration, two 
additional samples were drawn 30 and 45 min after drug administration and finally 
two samples were drawn between 120 and 240 min, during the assumed elimination 
phase after intranasal administration of dexmedetomidine into micro EDTA tubes 
for the determination of dexmedetomidine plasma concentrations. A 5 min time 
window was allowed in sampling times for the first three samples. A 10 min window 
was allowed for the fourth blood sample. Two blood samples were collected between 
120 and 240 min from drug administration in order to avoid blood sampling during 
MRI imaging. Actual sampling times were recorded and used in the data analysis. 
4.4.2  Analysis of drug and catecholamine concentrations in plasma  
In Studies I-II, concentrations of dexmedetomidine in plasma were determined with 
a validated (Guidance for Industry Bioanalytical Method Validation) reversed-phase 
high-performance liquid chromatography method with tandem mass spectrometric 
detection (HPLC-MS/MS; Shimadzu Prominence HPLC connected to an AB Sciex 
API4000 mass spectrometer), with some modifications to a previously described 
procedure (Ji et al. 2004). The lower limit of quantitation (LLOQ) was 0.05 ng/ml. 
The within- and between-run precision of the assay (coefficient of variation) was 
within 5% in the relevant concentration range. Concentrations of adrenaline and 
noradrenaline in plasma were measured in study I using HPLC and coulometric 
electrochemical detection, basically as described previously (Scheinin et al 1991), 
but now adapted to a dedicated HPLC system provided by Thermo Fisher Scientific 
(Waltham, MA, USA). The LLOQ for both catecholamines was 0.1 nM. The within- 
and between-run precision of the assay (coefficient of variation) was within 10% in 
the relevant concentration range. 
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4.5  Pharmacokinetic analysis and pharmacometric modeling 
4.5.1  Non-compartmental analysis 
In Studies I and II, the peak dexmedetomidine concentration (Cmax) and the 
corresponding time points (Tmax) were directly observed from the data. For each 
subject, the terminal log-linear phase of the plasma dexmedetomidine concentration-
time curve was identified visually, and the elimination rate constant (kel) was 
determined by regression analysis on the basis of at least four time points. The 
elimination half-life (t1/2) was then calculated from the equation t1/2 = ln 2 / kel. The 
area under the dexmedetomidine plasma concentration-time curve (AUC) was 
calculated using the trapezoidal method, with the linear trapezoidal rule for 
increasing concentrations and the logarithmic trapezoidal rule for decreasing 
concentrations. Apparent clearance (CL/F) and apparent volume of distribution of 
dexmedetomidine during the elimination phase (Vz/F) were also calculated, with 
non-compartmental methods based on the statistical moment theory. The 
pharmacokinetic analysis was carried out with WinNonlin software (version 4.1, 
Pharsight Corporation, Mountain View, CA, USA). 
4.5.2  Pharmacometric modeling 
The first order conditional estimation with the interaction method was applied to the 
data. A PK/PD model was constructed in a sequential manner; first a sequential 
pharmacokinetic model for intravenously administered dexmedetomidine was built, 
followed by a mechanistic absorption model for subcutaneously administered 
dexmedetomidine. A pharmacodynamic model was built for 
noradrenaline/adrenaline concentration-time data alongside a fixed 
dexmedetomidine pharmacokinetic model. Finally, effect models for 
pharmacodynamic parameters (i.e. systolic and diastolic blood pressure, HR, 
vigilance and performance) were developed separately for each parameter with 
variable reserved data files. Inter-individual variability on the fixed effects 
parameters in the model was specified using an exponential model: 
Ф𝑖𝑖 = 𝜃𝜃 ∗ 𝑒𝑒𝜂𝜂𝑖𝑖 
where Ф𝑖𝑖  represents the value of a fixed effect parameter for an individual, 𝜃𝜃 is the 
typical population value of the parameter, and 𝜂𝜂𝑖𝑖  accounts for the inter-individual 
variability of the ith individual from the population typical value. 
Inter-individual variability was introduced into all model parameters stepwise in 
nested models and accepted only if it led to a significant decline in the objective 
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function value (OFV), the ETA-shrinkage was <25%, and the model stability 
remained unaffected. In the pharmacokinetic model of dexmedetomidine with both 
administration routes, the residual variability in predicted concentrations was 
specified with a proportional error model: 
𝐶𝐶𝑖𝑖𝑖𝑖,𝑥𝑥 = 𝐶𝐶𝑖𝑖𝑖𝑖,𝑥𝑥 ∗ �1 + 𝜀𝜀𝑖𝑖𝑖𝑖,𝑥𝑥� 
An additive error model was used for noradrenaline and adrenaline concentrations 
as well as for the remaining pharmacodynamic parameters, 
𝐶𝐶𝑖𝑖𝑖𝑖,𝑥𝑥 = 𝐶𝐶𝑖𝑖𝑖𝑖,𝑥𝑥 +  𝜀𝜀𝑖𝑖𝑖𝑖,𝑥𝑥 
where x is one of the three substances, 𝐶𝐶𝑖𝑖𝑖𝑖,𝑥𝑥 is the jth observed concentration and 
𝐶𝐶𝑖𝑖𝑖𝑖,𝑥𝑥 is the model predicted concentration of the ith individual, and 𝜀𝜀𝑖𝑖𝑖𝑖,𝑥𝑥 is a normally 
distributed random variable to quantify the residual variability in the concentrations. 
Both 𝜂𝜂 and 𝜀𝜀 were assumed to be normally distributed random variables.  
Among the nested models, the differences in the OFV were used to discriminate 
between models. A significance level of 0.05 equivalent to a decline of 3.84 points 
in the OFV was used. Model performance was evaluated with standard goodness-of-
fit plots and prediction corrected visual predictive checks (Nguyen et al. 2017). 
Bootstrap analysis of the final models with 1000 replicates was carried out in order 
to calculate bias, standard errors and confidence intervals in the model parameters. 
4.6.  Analysis of pharmacodynamic effects 
4.6.1  Assessment of hemodynamics effects 
In Studies I and II, HR and in Study I, blood pressure was monitored continuously 
during follow-up and recorded at times of blood sampling. In Study III, HR was 
recorded continuously from the beginning to the end of the MRI procedure. In Study 
IV, HR was recorded continuously and MAP was measured at 5 min intervals from 
the beginning of the procedure until discharge from the PACU. HR and MAP were 
recorded before anesthesia induction, during wound incision, 1 h after anesthesia 
induction, during wound closure and in the PACU one hour after the operation. 
4.6.2  Assessment of sedative effects 
In Study I, psychomotor drug effects on vigilance and performance were assessed at 
times of blood sampling with a visual analogue scale (VAS). In Study II, 
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psychomotor drug effects on vigilance and performance were determined during 
blood sampling using a Comfort-B sedation scale (CBSS). The effect of 
dexmedetomidine on sedation was evaluated before administration of supplemental 
thiopental. 
In Study III, the aim of sedation was to maintain the Modified Observer’s 
Assessment of Alertness/Sedation Scale scores of the patients between 1 and 3, but 
the psychomotor drug effects of dexmedetomidine were not monitored. In Study IV, 
depth of sedation was monitored in the operation room using an entropy sensor 
(Entropy sensor; Datex-Ohmeda, Finland) to measure state entropy (SE) from frontal 
four-channel EEG. Effect site TCI concentrations of propofol and remifentanil, 
which all were recorded during wound incision, 1 hour after anesthesia induction 
and during wound closure. 
4.6.3  Assessment of respiratory effects 
Respiratory effects were monitored in all studies with pulse oximetry. In Study I, 
SpO2 was monitored continuously for 10 h after administration of subcutaneous or 
intravenous dexmedetomidine, and in Study II, from administration of intranasal 
dexmedetomidine until at least one hour after MRI in all patients. SpO2 was recorded 
in both studies at times of blood sampling.  
In Study III, SpO2 was monitored continuously during MRI. SpO2 as well as oxygen 
delivery were obtained from the anesthesia report. Lowest and highest values of 
SpO2 and use of (yes/no) supplemental oxygen administration were recorded. In 
Study IV, SpO2 was monitored continuously from the beginning of the procedure 
until discharge of patients from the PACU, but SpO2 was not included in the analysis 
of the study. 
4.6.4  Assessment of sympatholytic effects 
In Study I, plasma concentrations of adrenaline and noradrenaline were measured to 
assess the sympatholytic effects of dexmedetomidine. For adrenaline and 
noradrenaline concentrations, AUC was determined by using the trapezoidal rule in 
fractions of 0 to 0.5, 0 to 1, 0 to 2, 0 to 3 and 1 to 2 hours.  
In Studies II and III, the sympatholytic effects of intranasally administered 
dexmedetomidine were determined by monitoring HR and by analyzing the decline 
of HR from the baseline in beats per minute and in percentages.  
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In Study IV, the sympatholytic effects of intranasally administered 
dexmedetomidine were assessed by monitoring HR and MAP from the beginning of 
the procedure until discharge from the PACU and comparing the hemodynamic 
parameters between the two groups.  
4.6.5  Assessment of barbiturate- and opioid-sparing effects  
In Study III, the requirement of thiopental during MRI was assessed retrospectively 
from the patient records. A 50% reduction in thiopental consumption was considered 
clinically significant. In Study IV, postoperative opioid consumption within 2, 12, 
24, 36 and 48 h after the end of the surgery was assessed retrospectively from the 
patient records, converted to oral morphine equivalents (McPherson et al. 2010, 
Nielsen et al. 2016; Table 7) and compared between the two groups. A 15% reduction 
in postoperative opioid consumption was considered clinically significant.  
Table 7. Opioid conversion table to oral morphine equivalents (1 mg to indicated mg of oral 
morphine). 
Administration route Per orally Parenterally 
fentanyl - 300 
oxycodone  1.5 3 
pethidine - 0.4 
tramadol 0.2 - 
codeine 0.1 - 
Modified from McPherson et al. 2010 and Nielsen et al. 2016 
4.7  Safety and adverse events 
4.7.1  Assessment of local tolerability 
In Study I, the local tolerability of subcutaneously and intravenously administered 
dexmedetomidine was assessed with VAS scores provided by the study participants 
immediately prior to drug administration (baseline) and at 1, 5, and 10 h. Subjective 
effects (no local pain/strong pain, no irritation/strong irritation, no pruritus/strong 
pruritus, no numbness/total numbness) were recorded. In the visual inspection by the 
investigator, possible signs of local dermal irritation, inflammation, bleeding and 
swelling were recorded.  
In Study II, the local tolerability of intranasally administered dexmedetomidine was 
assessed by visual inspection by the investigator immediately prior to drug 
administration (baseline) and at 0.5 1, 2, and 4 h after administration of intranasal 
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dexmedetomidine. In the visual inspection conducted by the investigator, possible 
signs of local mucosal irritation, inflammation, bleeding and swelling were recorded. 
4.7.2  Assessment of safety 
In Studies I and II, the well-being of the study subjects was continuously monitored 
throughout the study sessions. Possible objective or subjective adverse events as well 
as concomitant treatments used to treat them were recorded in the case report form 
(CRF). 
In Studies III and IV, possible objective or subjective adverse events as well as 
concomitant treatments used to treat them were collected from the hospital’s patient 
information system and anesthesia reports, and possible adverse events (e.g. nausea 
and vomiting) related to the procedures were manually identified. 
4.7.3  Reporting of Adverse Events (AE) 
In Studies I and II, all AEs were documented and reported by the investigator from 
the moment of detection until the end of follow-up. All subjects were monitored at 
the study site for a minimum of 10 hours after drug administration in study I and for 
a minimum of 4 hours after drug administration in Study II. All AEs were recorded 
by the investigator in the appropriate space in the CRFs. AEs were detailed in CRFs 
according to the EMA guidelines. 
In Studies III and IV, AEs were not documented or reported in real time, due to the 
retrospective nature of the studies. Unexpected difficulties during anesthesia had 
been recorded in the anesthesia report, which was evaluated for each patient. 
Possible AEs (eg. bradycardia or vomiting) related to the procedures were manually 
identified and reported. 
4.8  Statistical analysis 
4.8.1  Study hypotheses and outcomes 
In Study I, our working hypothesis was that subcutaneously administered 
dexmedetomidine would be efficiently absorbed with attenuated sympatholytic 
effects compared to intravenous administration. The primary outcome variables 
determined in Study Ia were the observed concentrations of dexmedetomidine in 
plasma and its calculated pharmacokinetic parameters. The secondary variables were 
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HR, blood pressure, plasma adrenaline and noradrenaline concentrations, sedative 
effects, and possible local adverse effects.  
In Study Ib, the aim was to build a PK/PD model that would account for the 
disposition kinetics of intravenous and subcutaneous dexmedetomidine, accurately 
describe the complex mechanism of dexmedetomidine absorption from the site of 
administration and mechanistically predict the effects of dexmedetomidine on HR, 
blood pressure as well as on subjective assessments of vigilance and performance. 
In Study II, we hypothesized that intranasal doses of 2-3 µg/kg of dexmedetomidine 
would lead to the previously defined (i.e. 0.3-0.7 ng/ml) clinically effective plasma 
concentrations in children. The primary outcomes of the study were Cmax and time to 
Cmax (Tmax). The secondary outcomes were area under the concentration-time curve 
(AUC0-4h) and the pharmacological effects caused by single intranasal 
dexmedetomidine. The effect of age on dexmedetomidine pharmacokinetics was 
also evaluated. 
In Study III, we hypothesised that intranasally administered dexmedetomidine (3 
µg/kg) would markedly reduce the amount of additive barbiturate needed for MRI 
sedation. Our primary outcome was to compare the thiopental requirement after 
intranasal dexmedetomidine was added to the sedation protocol of pediatric patients 
undergoing MRI. Our secondary outcomes were to compare the lowest HR and SpO2 
values recorded, and the need for supplemental oxygen during the MRI.  
The primary outcome of Study IV was postoperative opioid consumption in 
morphine dose equivalents. Perioperative MAP and HR were secondary outcomes. 
Our hypothesis was that intranasal administration of low doses of dexmedetomidine 
to supine anesthetized patients would exert beneficial effects on postoperative opioid 
consumption and hemodynamics. 
4.8.2  Sample sizes  
On the basis of previous studies (Iirola et al. 2011a, Scheinin et al 1992), it was 
calculated that 8 subjects would be needed for Study I to demonstrate a 30% 
difference in the AUC of plasma dexmedetomidine at a level of significance of p = 
0.05 and power of 80%. To be prepared for drop-outs, we initially recruited 10 
subjects and later recruited another replacement subject. For study II, we estimated 
that fifty pediatric patients would be sufficient based on similar pharmacokinetic 
studies conducted in children (Bradley et al. 2014, Chrysostomou et al. 2014, Nielsen 
et al. 2014). 
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The sample sizes of Studies III and IV were based on previous experience in similar 
retrospective studies (Gyanesh et al. 2014, Boriosi et al. 2017; Su et al. 2016, Ökmen 
et al. 2017). We evaluated the statistical power achievable with the planned sample 
sizes by calculating confidence intervals. 
4.8.3  General statistics 
The results are expressed as median (range or IQR), mean (standard deviation) or 
geometric mean (90% confidence intervals), depending on the distribution of the 
parameter. A qualified statistician chose and recommended specific tests for 
evaluating associations between the variables and differences between groups or 
treatments. In all studies, the data were evaluated for normality of distributions using 
probit plots and Shapiro–Wilk’s W-test. Differences were regarded as significant at 
p < 0.05. 
The data were analysed by using statistical programs in R language for Statistical 
Computing, version 3.3.2 (R Core Team 2017), in Rstudio, version 1.0.136 (RStudio 
Team 2016); R language for Statistical Computing, version 3.4.2; JMP Pro, version 
13.0 for Mac (SAS Institute Inc., Cary, NC, USA) and SAS System programs, 
version 9.4. for Windows (SAS Institute Inc., Cary, NC, USA) in Studies I, II and 
III-IV, respectively. NONMEM 7.3.0 (ICON Development Solutions, Ellicott City, 
MD, USA) was used for pharmacometric modeling. 
4.8.4  Statistical inferences 
In the pharmacokinetic Studies I and II, dexmedetomidine and catecholamine 
concentrations were log-transformed prior to computing pharmacokinetic 
parameters for each individual, but non-transformed results are reported. In Study II, 
concentrations were dose-corrected by the total dose before analysis. 
In Study I, differences in pharmacokinetic variables were analysed using paired t-
tests. Pharmacodynamic data were analysed using analysis of variance (ANOVA) 
for repeated measurements. Data were log-transformed before statistical analysis, 
but non-transformed results are reported.  
In Study II, pharmacokinetic parameters and pharmacological effects were compared 
with one-way ANOVA, while Tmax and the other time-related parameters were 
compared with the Kruskal-Wallis test. Levene's test for homogeneity of variances 
was used prior to ANOVA. The associations of dexmedetomidine concentrations in 
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plasma and the pharmacokinetic parameters with pharmacological effects were 
evaluated using Pearson’s product moment correlation. 
In Study III, primary outcomes were tested using the Kruskal-Wallis test and 
continued with age group comparisons (corrected with the Steel-Dwass method). 
Nominal data were tested using chi-square analysis. 
In Study IV, a further subgroup analysis was performed between those patients 
receiving and not receiving NSAID therapy, by using the Kruskal-Wallis test and 
Wilcoxon’s rank-sum test. Nominal data were tested using chi-square analysis. 
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V  RESULTS 
5.1  Non-compartmental pharmacokinetics of dexmedetomidine after 
subcutaneous administration 
We included 8 subjects in the pharmacokinetic analysis of Study Ia, since two 
subjects were excluded before the intravenous phase, one for safety reasons and one 
for violation of the subject inclusion criteria. Median (range) Tmax of 
dexmedetomidine was 15 (15-240) min after subcutaneous administration. The mean 
(range) bioavailability of subcutaneous dexmedetomidine was 81 (49-95)%. The 
mean (SD) Cmax of dexmedetomidine in plasma was 0.3 (0.1) ng/ml (Figure 7). The 
pharmacokinetic results of Study Ia are summarized in Table 8. 
Table 8. Pharmacokinetic parameters after 1 µg/kg doses of dexmedetomidine administered 
intravenously and subcutaneously to eight healthy volunteers. 
Parameter Intravenous Subcutaneous P 
Cmax (ng/ml) 2.4 (0.4) 0.3 (0.1) < 0.001 
Tmax (h) 0.17 (0.08-0.17) 0.25 (0.25-4) <0.001 
AUC0-10 h (ng min/l) 117 (20) 74 (21) 0.0019 
AUC0-∝ (ng min/l) 121 (21) 109 (40) 0.328 
CL/F (ml/min/kg) - 903 (345) - 
Vz/F (l) - 286 (81) - 
CL (ml/min/kg) 677 (109) - - 
Vss (l) 92.8 (9.9) - - 
t1/2 (min) 1.9 (0.3) 3.8 (0.9) < 0.001 
F (%)a - 81 (49-97) - 
Data are shown as mean and SD, except for Tmax, where median and range are shown. 
a Statistical testing and bioavailability are based on data from those subjects who completed both treatment 
visits (n=8) 
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Figure 7. Mean (SD) plasma concentrations of dexmedetomidine after administration of 1 µg/kg of 
dexmedetomidine intravenously to eight (a) and subcutaneously to ten (b) healthy volunteers.  
5.2  Pharmacometric modelling of subcutaneously administered 
dexmedetomidine 
A semi-mechanistic structural model was developed. A two-compartment 
mammillary model proved to be better than a three-compartment model in explaining 
dexmedetomidine disposition kinetics [change in OFV = -331 and -346, 
respectively]. Plausible parameter estimates [CL1 = 44.5 l/h, V1 = 18.3 l, CL2 = 115 
l/h, V2 = 77.6 l] and visual predictive checks described the model adequateness for 
depicting the data. In the second stage, the absorption of dexmedetomidine after 
subcutaneous administration was captured by the addition of a fat depot 
compartment. This assumption is supported by the high lipid solubility of 
dexmedetomidine. Rate constants for drug movement from this depot to the 
subcutaneous fat layer (Ka ,FAT), from the depot to the central compartment (Ka,FAST) 
and from subcutaneous fat to the central compartment (Ka ,SLOW) were estimated with 
adequate precision [Ka, FAT = 3.11, Ka, FAST = 1.11 and Ka, SLOW = 0.13].  
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Next, indirect response models were employed to explain the dexmedetomidine-
induced decreases in noradrenaline and adrenaline release. In the final stage models 
were built for subjective effects on vigilance and cognitive performance, as 
measured with visual analogue scales. Emax models with effect compartments were 
implemented and an additive model was used to estimate the effect of noradrenaline 
release as a surrogate measure of vigilance and performance as pharmacodynamic 
variables. Dexmedetomidine 𝐸𝐸𝐶𝐶50 for causing 50 % inhibition of noradrenaline 
release was estimated at approximately 0.3 ng/mL, which is numerically close to the 
concentrations achieved in the study subjects with subcutaneous dosing of 1 μg/kg, 
and much lower than the drug concentrations achieved after intravenous dosing. All 
attempts to model epinephrine failed, indicating that the models were easily over-
parametrised to provide a numerically stable predictive model output. 
For blood pressure models, the net effect was coded as a sum of hyper- and 
hypotensive effects of dexmedetomidine due to vasoconstriction on peripheral 
arteries and sympatholysis mediated via the central nervous system. Reductions in 
blood pressure after dosing of dexmedetomidine were assumed to result from 
reduced noradrenaline concentrations in the noradrenaline release compartment, and 
a sigmoidal model with a biophase was utilised to estimate individual systolic and 
diastolic blood pressure values. Hypotensive effects of noradrenaline concentration 
fluctuations and hypertensive blood pressure effects due to plasma dexmedetomidine 
concentrations on systolic and diastolic blood pressure were defined in the model. A 
HR model combined the sympatholytic effect and other input from the central 
nervous system, predicted from arterial blood pressure levels. We added an 
inhibitory effect of systolic blood pressure on HR, mediated by baroreceptor reflex 
activation in the central nervous system, to account for the misfit in the HR model, 
which resulted in an unbiased output. We hypothesized, that HR reductions after 
dexmedetomidine administration included an effect component that is dependent on 
the blood pressure levels and mediated by the baroreceptor reflex. Model-predicted 
systolic blood pressure estimates from our final blood pressure model were used to 
drive an indirect response model for HR regulation. Subjective effects of 
dexmedetomidine were coded using a biophase and sigmoidal direct effect models. 
5.3  Pharmacokinetics of dexmedetomidine after intranasal 
administration in pediatric patients 
Data from 50 patients were analysed in Study II. The mean (SD) dose-corrected Cmax was 
0.011 litre-1 (0.0051) and the median interquartile range (IQR) Tmax was 37 (30-45) min. 
We found significant negative associations between dose-corrected Cmax and subject age 
[Pearson’s r = -0.58; 95% confidence interval (CI) -0.74 – -0.37, p < 0.001] and dose-
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corrected AUC0-4 h versus age (r = -0.53, 95% CI -0.70 – -0.29; p < 0.001). Tmax did not 
correlate with age (r = -0.14; 95% CI -0.14 - 0.39; p = 0.35) (Figure 8 and Table 9). 
Figure 8. Individual concentration-time curves after intranasal 3 µg/kg dosing of dexmedetomidine 
as a nasal spray in three age groups of children. 
Table 9. Dose-corrected pharmacokinetic parameters of dexmedetomidine after administration of 
2-3 µg kg-1 doses as nasal spray to 50 ambulatory pediatric patients. 
Parameter All patients Age 0-2 yr Age 2-6 yr Age 6-11 yr P 
Cmax (ng/ml) 0.54 (0.17) 0.46 (0.11) 0.51 (0.17) 0.61 (0.18) - 
Cmax/D (1/litre) 0.011 (0.0051) 0.016 (0.0048) 
0.011 
(0.0046) 
0.0086 
(0.0040) < 0.001 
Tmax (min) 37 (30 – 45) 35 (22 – 43) 32 (28 – 45) 41 (30 – 47) 0.52 
AUC0-4 (ng/min/ml) 68 (23) 61 (21) 69 (25) 77 (21) - 
AUC0-4 /D (min/ml) 1.40 (0.61) 1.90 (0.51) 1.42 (0.66) 1.14 (0.45) 0.0035 
Data are shown as mean and SD, except for Tmax, where median and IQR are shown. D, dose (µg) of 
dexmedetomidine 
5.4  Barbiturate and opioid sparing effects of intranasal 
dexmedetomidine 
5.4.1  Barbiturate sparing effect 
In Study III, 200 patients were included in the analysis. Significantly smaller induction 
and total doses of thiopental were needed for completion of the planned MRI procedure 
in all dexmedetomidine groups as compared to the corresponding control group. The 
difference was statistically significant in all three clinically relevant age groups. The 
median (IQR) cumulative thiopental requirement during MRI was 4.4 (2.7–6.0) mg/kg/h 
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compared to 12.4 (9.8– 14.8) mg/kg/h in the dexmedetomidine and control groups, 
respectively (median difference 7.9 mg/kg/h, 95% CI: 6.8–8.8, P < 0.001).  
The median (IQR) induction doses of thiopental before MRI were 1.8 (1.2–2.3) 
mg/kg in the dexmedetomidine treated children, almost three times lower than the 
value in the control group, 5.1 (4.6–6.2) mg/kg (median difference 3.3 mg/kg/h, 95% 
CI: 3.1–3.6, P < 0.001) (Figure 9). 
  
 
Figure 9. Box plots showing the difference in induction doses (mg/kg) of thiopental between the 
dexmedetomidine and thiopental groups (A) and in the three clinically significant age groups after 
dexmedetomidine + thiopental or only thiopental (B). Below, the cumulative doses of thiopental 
(mg/kg/h) are shown for the dexmedetomidine and thiopental groups (C) and for the three clinically 
significant age groups (D). 
5.4.2  Opioid sparing effect 
In Study IV, 120 patients were included in the analysis. The cumulative postoperative 
opioid requirement (in oral morphine equivalents) was significantly less in the 
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dexmedetomidine group as compared to the control group (26.3 mg, 95% CI 15.6 to 
36.4, P < 0.001). The cumulative dose was significantly different between the groups 
at 12, 24 and 36 h postoperatively (p = 0.01; p = 0.001; p < 0.001) (Figure 10). 
 
Figure 10. Box plots showing the cumulative postoperative opioid requirement in the control and 
dexmedetomidine groups. Results are reported as oral morphine equivalent doses within 2, 12, 24, 
36 and 48 h of surgery. 
5.5  Hemodynamic and sympatholytic effects 
5.5.1  Hemodynamic effects 
Compared to subcutaneous dosing, mean MAP was significantly lower during 0–
120 min (P < 0.032) after intravenous administration of dexmedetomidine in Study 
I. HR decreased initially after intravenous dosing, but there were no statistically 
significant differences between the two administration routes when maximum 
decreases or epochs over 0–30 or 0–60 min after drug administration were tested. 
In Study II, the mean (SD) decrease in HR after dexmedetomidine dosing was 16 
(8.9) bpm and the lowest mean (SD) HRs before administration of supplemental 
thiopental in the three age groups were 95 (11), 76 (13) and 69 (10) bpm, respectively 
(Figure 11).  
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In Study III, the mean (SD) of the lowest measured HR was 78 (16) bpm in the 
dexmedetomidine group compared to 92 (12) bpm in the thiopental group (P < 0.001) 
(Figure 11). Blood pressure was not routinely recorded in the subjects of this study. 
In Study IV, the HR and MAP of the dexmedetomidine group were lower compared 
to the control group in the PACU (P = 0.008; P < 0.001). The dexmedetomidine 
group had higher MAP values intraoperatively (P < 0.001), but also used more 
intraoperative vasoactive medication (P = 0.01). There was no difference in 
intraoperative bleeding between the two groups (P = 0.86). 
5.4.2  Effects on catecholamines 
In Study I, plasma noradrenaline concentrations remained significantly smaller (P < 
0.001) after intravenous than subcutaneous dexmedetomidine during the entire 
sampling period, 3 h after dosing, and the calculated noradrenaline AUC0–180 min was 
significantly smaller (P < 0.001) after intravenous than after subcutaneous 
dexmedetomidine (Figure 12). Plasma adrenaline concentrations were significantly 
lower for the first 60 min after intravenous drug administration (P = 0.037), but after 
that time point, there were no significant differences between the treatments.  
 
Figure 11. Relative change in heart rate (%) after administration of 1 ug/kg of intravenous 
dexmedetomidine (•) or subcutaneous dexmedetomidine (♦) to healthy volunteers or 2-3 ug/kg of 
intranasal dexmedetomidine to pediatric patients* (o). 
*patients received additional thiopental for sedation 60 min after administration of dexmedetomidine 
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Figure 12. Mean (SD) adrenaline and noradrenaline concentrations in plasma after administration 
of 1 µg/kg of dexmedetomidine intravenously (●) to eight and subcutaneously (o) to ten healthy 
male volunteers. 
5.5  Sedative effects 
Subjective effects of dexmedetomidine on vigilance in Study I are shown in Figure 
13. The scores for vigilance were significantly lower at 0–60 min after intravenous 
injection than after subcutaneous dosing (P < 0.001), but at later time points, the 
subjects tended to be more sedated after subcutaneous than after intravenous 
administration. Concentrations of dexmedetomidine in plasma usually associated 
with sedative effects (i.e., > 0.2 ng/ml) were present for 4 h in both groups (Figure 
13). 
In Study II, maximal sedation after administration of intranasal dexmedetomidine 
was achieved in 45 min. The median (IQR) decrease in CBSS was 8 (6-9) points 
from the baseline (Figure 13). Dexmedetomidine concentrations in plasma > 0.2 
ng/ml were achieved in all patients. However, 47 patients required additional 
sedation to achieve the completion of the MRI procedure and thus were dosed with 
thiopental. The median (IQR) thiopental dose was 2.6 (1.6-5.1) mg/kg; the median 
times to thiopental administration were 68 min, 66 min and 86 min in the three age 
categories, respectively. In Study III, depth of sedation was not recorded.  
In Study IV, depth of sedation was monitored intraoperatively with SE, which was 
recorded at three different time points. There were no statistically significant 
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differences at any time point between the dexmedetomidine and control groups. 
There was also no statistically significant difference in PACU time between the 
groups. 
5.6  Respiratory effects 
In Study I, SpO2 remained unchanged in all patients. In Study II, SpO2 remained 
clinically acceptable in all patients after administration of dexmedetomidine. 
Immediately after the thiopental administration, one patient received supplemental 
oxygen since his SpO2 value decreased to 91%. 
In Study III, thirty-three (33%) of the patients in the control group received 
supplemental oxygen whereas only two (2%) of the dexmedetomidine group patients 
needed oxygen (P < 0.001). Despite the less frequent oxygen administration in the 
dexmedetomidine group, the lowest observed peripheral oxygen saturation reading 
was higher in these patients as compared to the control group (P < 0.001). In Study 
IV, there was no difference in the frequency of oxygen administration between the 
two groups (p = 0.63).  
Figure 13. Sedative effects of dexmedetomidine after intravenous (●) or subcutaneous (o) 
administration of 1 ug/kg to healthy volunteers and after intranasal (●) administration of 2-3 ug/kg 
of dexmedetomidine to pediatric patients*. Left y-axis represents VAS scale for vigilance (Study I) 
and right y-axis represents CBSS scores (Study II). 
*the patients received additional thiopental for sedation at 60 min after administration of dexmedetomidine 
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5.7  Safety and tolerability 
One subject was withdrawn from Study I for safety reasons after the subcutaneous 
administration phase due to emergence of bradycardia between 32 to 39 bpm at 1 h 
after drug administration; this symptom resolved after 4 h without interventions and 
was not associated with subjective symptoms. 
In Studies II and III, two patients (aged 4.7 and 7.8 years) received atropine for 
bradycardia (36 and 39 bpm, respectively) soon after receiving thiopental one hour 
after administration of 3 µg/kg intranasal dexmedetomidine.  
In Study II, one patient receiving 2 µg/kg of intranasal dexmedetomidine and 5 
mg/kg of intravenous thiopental vomited after the MRI procedure. In Study III, two 
patients in the dexmedetomidine group and two patients in the control group reported 
mild nausea after MRI but no vomiting was recorded.  
In Study II, the reported adverse events were mild and mostly related to an 
unpleasant feeling in the nasal mucosa (3 out of 50 children) immediately after 
administration of the nasal spray. Nasal irritation was not observed in nor reported 
by any of the patients, but crying was observed in sixteen (32%) patients and a runny 
nose occurred in eight (16%) patients. In Study III, local irritation was not reported. 
In Study IV, no adverse events were recorded. 
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VI  DISCUSSION 
6.1  Methodological aspects 
6.1.1  Study I 
A randomized, controlled and balanced study design was used. A cross-over design 
was chosen in order to reduce the effect of inter-individual variation. The cross-over 
design also helped to keep the number of volunteers small as each subject served as 
his own control. In order to further reduce inter-individual variability, we recruited 
young, normal-weight healthy male volunteers. Only eight subjects received 
intravenous dexmedetomidine; this is the reason why we decided to include only 8 
subjects in the analysis of Study Ia. Data from all subjects were included in the 
analysis of Study Ib. 
Dexmedetomidine dosing was based on the product label information and 
corresponded with the dosages that have been previously suggested for palliative 
sedation (Kent et al. 2005, Soares et al 2002). It would have been interesting to study 
bolus dosing of subcutaneously administered dexmedetomidine, but since 
intravenous bolus dosing is not recommended, we chose to apply the same 
administration rate in both treatments in order to maintain comparability. 
We collected plasma samples for concentration measurements of dexmedetomidine 
for 10 h and for concentration measurements of catecholamines for 3 h. Despite this 
relatively long sampling period, the fraction of extrapolated AUC0-∝ was 28% in the 
subcutaneous phase. It would have been more informative to collect blood samples 
over a longer period. Similarly, measurement of catecholamines could have been 
longer, since both adrenaline and noradrenaline concentrations still appeared to be 
declining 180 min after drug administration. However, any differences in the 
adrenaline and noradrenaline responses between the two administration routes were 
probably most likely to be evident already during the first hour after drug 
administration. 
A wash-out period of 3 weeks was utilized to minimize the risk of possible carry-
over effects. Pre-dose blood samples were drawn for controlling possible carry-over 
in the second study session, but none of the pre-dose samples of the study subjects 
exceeded the lower limit of dexmedetomidine quantification. 
Study Ib was a PK/PD modeling study based on the subject population of Study Ia, 
except that all 10 subjects were included in the analysis. Modelling of the absorption 
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of dexmedetomidine from subcutaneous injection site proved to be challenging. 
Several attempts to model topical dexmedetomidine absorption, including first order 
absorption, single Weibull absorption and biphasic absorption with slow absorption 
(Ka, slow), did not yield satisfying models. Thus, a biphasic fat compartment model 
with fast absorption (Ka, fast) and slow absorption (Ka,slow) processes was devised and 
a fat layer permeation constant (Kfat) was used. This model described the movement 
of dexmedetomidine into a subcutaneous fat layer and from there to the circulation. 
Our model was able to capture the dexmedetomidine, noradrenaline and adrenaline 
concentration-time profiles and pharmacodynamic effects quite well. Compared to 
intravenous administration, the HR decreases were less pronounced after 
subcutaneous dexmedetomidine while the central nervous system effects (as 
reflected by drowsiness) were more pronounced. 
Although our pharmacometric model captured the data well and the model can be 
utilized in simulation studies, it should be emphasized it is solely based on data from 
healthy volunteer subjects. In addition, only a short dexmedetomidine infusion was 
employed.   
6.1.2  Study II 
Our main objective was to evaluate drug absorption after intranasal dosing. We 
decided to recruit pediatric patients with a wide age range, but recruitment of the 
youngest age group (1 month to 2 years) proved to be challenging due to the small 
number of such patients actually requiring sedation for MRI. This resulted in an 
uneven distribution of patients in the three clinically relevant age groups. The timing 
of the blood sampling was not perfect for a non-compartmental analysis, but we were 
able to obtain over 300 blood samples from 50 pediatric patients, which is more than 
in earlier similar pharmacokinetic studies conducted in children (Bradley et al. 2014, 
Chrysostomou et al. 2014, Nielsen et al. 2014). Experimental PK/PD modeling will 
be performed for the same patient population in the future. 
Based on earlier observations in healthy adult volunteers (Iirola et al. 2011a), we 
drew two samples during the assumed absorption phase, two samples during the 
distribution phase and two samples to cover the elimination phase. It would have 
been more informative to collect further blood samples, but as our patients were 
discharged after four hours, further follow-up and blood sampling was not possible. 
Despite such a relatively short sampling period, we were able to capture informative 
concentration-time profiles for each patient. 
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The administration of dexmedetomidine as a nasal spray has been investigated 
mainly in preoperative applications with a dosing range of 0.5 to 2 µg/kg (Yuen et 
al. 2008, Talon et al. 2009, Cimen et al. 2013). We wanted to study higher doses 
based on previous reports where up to 9 µg/kg/h doses of intravenous 
dexmedetomidine have been used for pediatric patients undergoing MRI (Mason et 
al. 2010, Siddappa et al. 2011). At the time when our study was initiated, there was 
no prior pharmacokinetic information about intranasal dexmedetomidine in children.  
The dose volumes of delivered intranasal dexmedetomidine varied from 240 µl to 
1200 µl, which by far exceeds the volumes usually considered as ideal. Although the 
largest doses were divided into both nostrils, the used volumes were still two to six 
times larger than those employed in commercial nasal spray products (Djupesland et 
al. 2013). This may have affected intranasal drug absorption negatively, and calls for 
the development of a drug product with a higher concentration of dexmedetomidine, 
or improved drug delivery systems compared to the one used in this study, if 
intranasal application is to be clinically applicable. 
The Ramsey Sedation Scale and Richmond Agitation and Sedation Scale are 
commonly employed for monitoring the depth of sedation in ambulatory pediatric 
patients. We chose to use the CBSS to assess the depth of sedation as this scale is 
routinely used in our pediatric ICU. The use of the CBSS does not need any verbal 
or physical stimulation, which can be considered an advantage in pediatric patients 
that are breathing spontaneously and are expected to lie motionless. Sedation with 
dexmedetomidine at doses of 2-3 µg/kg was considered clinically acceptable as 
decreases of 6 or more points in the CBSS have been suggested to indicate a good 
response to sedative agents in pediatric patients (Boerlage et al 2015). 
6.1.3  Study III 
We compared retrospectively two different pediatric MRI sedation protocols. Our 
hypothesis was that intranasally delivered dexmedetomidine would decrease the 
requirement of intravenous thiopental. We also hypothesized that the risk of 
respiratory depression caused by thiopental would be reduced when intranasal 
dexmedetomidine was used as premedication. 
The number of patients included in the study was sufficient, since the observed 
differences in thiopental consumption were highly significant in all three age 
categories. Considering respiratory depression evoked by thiopental, it would have 
been more informative to measure the respiratory rate and end tidal CO2 with nasal 
capnography. Although respiratory rate was not reported, SpO2 recordings during 
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MRI sedation were significantly higher in the dexmedetomidine group, in spite of 
the higher frequency of supplemental oxygen administration in the control group. 
We measured sympatholytic effects caused by dexmedetomidine premedication by 
recording HR. It would have been more informative to investigate also blood 
pressure during the MRI in both groups, but this was not possible since blood 
pressure was not routinely measured in the MRI unit. However, the effect of 
intranasally administered dexmedetomidine on the blood pressure of pediatric 
patients has been previously evaluated and doses of 3 µg/kg have not been found to 
cause clinically significant hypotension or hypoperfusion (Li et al 2015). 
Furthermore, the incidence of hypertension has been low when higher doses of 
dexmedetomidine have been given intravenously to pediatric patients undergoing 
MRI (Mason et al 2010). 
6.1.4  Study IV 
Study IV was a retrospective analysis seeking to correlate the use of intranasally 
administered dexmedetomidine with opioid use after total hip replacement 
surgery.  We included healthy ASA 1-2 patients with body weight between 50 and 
100 kg in order to maintain the dosage of intranasal dexmedetomidine between 0.5 
and 1.0 µg/kg and in order to avoid confounders related to comorbidity. All patients 
received total intravenous anesthesia (TIVA), which has been associated with 
excellent recovery in outpatient surgery (Bruderer et al. 2017). However, the use of 
remifentanil as an anesthetic agent may carry a risk for hyperalgesia (de Hoogd et 
al. 2016), and multimodal management of anesthesia and analgesia in patients 
undergoing total hip arthroplasty under TIVA has been considered warranted 
(Stevenson et al. 2018).  
All patients in our study received perioperatively oral paracetamol, local anesthetic 
infiltration around the hip joint and intravenous betamethasone, which all have been 
shown to reduce postoperative opioid consumption compared to placebo in patients 
undergoing total hip arthroplasty (Hickman et al 2018, Murphy et al. 2012, Fan et 
al. 2018). Our results suggest that the use of intraoperative low-dose 
dexmedetomidine significantly reduced postoperative opioid consumption 
compared to the control group, despite the concomitant administration of other 
analgesic adjuvants. Although in patients undergoing total hip arthroplasty, 
concomitant NSAIDs can ease postoperative pain as compared to placebo (Zhou et 
al. 2001), NSAIDs were not given to all patients because of various contraindications 
(e.g. asthma). A post hoc subgroup analysis showed a statistically significant 
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difference in the postoperative opioid consumption between the two groups also 
when NSAID use was taken into account. 
We included fentanyl administration in the analysis of the primary endpoint, but 
since all study patients received 100 µg of intravenous fentanyl after termination of 
the TIVA, administration of fentanyl could well have been removed from the 
analysis of postoperative opioid consumption. This would have increased the 
difference in postoperative opioid consumption between the two groups.  
6.2  Pharmacokinetics of dexmedetomidine after subcutaneous 
administration 
The pharmacokinetics of extravascularly administered dexmedetomidine has mostly 
been studied in healthy volunteer subjects (Dyck et al. 1993a, Anttila et al. 2003, 
Iirola et al. 2011a). Our current findings suggest that dexmedetomidine has a similar 
bioavailability after subcutaneous, intranasal, and intramuscular administration and 
confirm that its bioavailability is sufficient for clinical efficacy also after 
subcutaneous administration. 
The bioavailability of subcutaneous dosing was 36% smaller during the sampling 
period (AUC0–10 h) when compared to intravenous dosing. When AUC was 
extrapolated to infinity (AUC0–∝), the mean bioavailability of subcutaneously 
administered dexmedetomidine was 81%. The pharmacokinetic parameters 
determined for intravenous dexmedetomidine were in line with earlier reports (Dyck 
et al 1993b). 
Previous studies have shown that intravenous administration of dexmedetomidine 
evokes dose-dependent decreases in HR and MAP, concomitantly with decreases in 
plasma catecholamines. However, initial hypertension may occur with high plasma 
concentrations related to a rapid administration of dexmedetomidine (Kallio et al 
1989, Ebert et al 2000, Snapir et al 2006). The hemodynamic, sedative and 
sympatholytic effects of subcutaneously administered dexmedetomidine emerged 
significantly more slowly when compared with intravenous administration. In order 
to diminish dexmedetomidine-induced hypertension and bradycardia after 
intravenous dosing, we used 10-min constant-rate infusions with both administration 
routes. Intravenous dosing did not result in hypertension, but significant decreases 
were seen in HR and blood pressure. Compared to this, subcutaneous administration 
was associated with smaller reductions in HR and MAP, which may reduce the risk 
of hemodynamic depression compared to intravenous dosing. 
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Subcutaneous dosing resulted in lower peak plasma concentrations compared to 
intravenous administration, but similar plasma concentrations were measured 3 h 
after dexmedetomidine dosing during both study phases. In accordance, the onset of 
sedation was delayed after subcutaneous dexmedetomidine compared to intravenous 
administration. Although there were no statistically significant differences in the 
duration of the sedative and hemodynamic drug effects between the two 
administration routes, the effects appeared to be reversed slightly more slowly after 
subcutaneously dosing compared to intravenous administration. 
Pronounced inhibition of sympathetic nervous system activity was reflected by 
reduced plasma noradrenaline concentrations after intravenous administration of 
dexmedetomidine. The onset of this effect was less abrupt and the reductions were 
smaller after subcutaneously injected dexmedetomidine.  
Study Ib aimed to create a PK/PD model that would describe the absorption of 
dexmedetomidine from the subcutaneous site of dosing. The mechanism-based 
PK/PD model of subcutaneously administered dexmedetomidine had several unique 
features. Dexmedetomidine has an octanol/buffer partition coefficient of 2.8, which 
allows entrance of the drug into fat tissue and slows its systemic absorption. A 
biphasic absorption model was therefore devised such that a fast absorption process 
was responsible for the influx of drug from the subcutaneous depot into the systemic 
circulation and a fat layer permeation constant was introduced to depict drug 
movement into the subcutaneous fat layer. A slow absorption process described the 
zero-order drug release from the subcutaneous fat layer. Although the scenario 
represents a biphasic absorption process, no strict criterion was coded into the model 
to describe the temporal shift between the two processes, and these were modelled 
simultaneously.  
The pharmacodynamic endpoints of HR and systolic and diastolic blood pressure are 
to some extent dependent on the biological concentrations of noradrenaline and 
adrenaline. However, due to the lack of a validated adrenaline model, these 
pharmacodynamic variables were assumed to be functions of noradrenaline 
concentrations only. The noradrenaline concentrations at the release compartment 
were used as the key determinant of the HR and systolic/diastolic blood pressure 
effect. In spite of these limitations, we could implement a combination of both 
hypertensive and hypotensive effects into our model for blood pressure. Finally, to 
model subjective effects, we assumed that the apparent noradrenaline concentrations 
at the release (synaptic) compartments were driving these with no other contributing 
mechanisms. Compared to intravenous administration, the HR decreases were less 
affected after subcutaneous dexmedetomidine while the central nervous system 
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effects (as reflected by drowsiness) were more sensitive. The output from the final 
model exhibits adequate model performance, plausible model parameter estimates 
with low relative standard error values, and a reasonable model fit as demonstrated 
by the standard GOF plots and visual predictive checks. Although our 
pharmacometric model captured the data well and we believe that the model can be 
utilized in simulation studies, it is emphasized that it is solely based on data from 
healthy volunteers. In addition, only a short dexmedetomidine infusion was 
employed. 
6.3  Pharmacokinetics of intranasal dexmedetomidine in pediatric 
patients 
Intranasal dexmedetomidine was rapidly absorbed in pediatric patients and Cmax was 
achieved in a median time of 37 min. There was, however, extensive inter-individual 
variability between study subjects, as previously reported in healthy adult volunteers 
(Iirola et al. 2011a, Li et al. 2018). One main reason for the inter-individual 
variability may be inadequate absorption of the drug related to unsuccessful drug 
administration and/or the large dosing volumes. The youngest age group (0-2 yr) had 
significantly higher dose-adjusted values of Cmax and drug exposure (AUC0-4 h) 
compared to the older patients. Peak concentrations might even continue to decrease 
with age, since the dose-corrected Cmax calculated for adult healthy volunteers (Iirola 
et al 2011a) was smaller (0.0060) than that now found in the oldest age group of our 
study (0.0086). This correlation of Cmax with age may be linked to the larger dosing 
volumes needed in the older subjects.  
A recent study (Miller et al. 2018) evaluated the pharmacokinetics of intranasal 
dexmedetomidine in twelve pediatric patients (age 6-44 mo) undergoing 
cardiopulmonary bypass. Half of the patients received 1 μg/kg and the others 
received 2 μg/kg of intranasal dexmedetomidine. Median Cmax of dexmedetomidine 
was 0.2 and 0.36 ng/ml and median Tmax was 47 and 46 min after the two different 
dosages. In our study, the mean Cmax (0.54 ng/ml after a mean dose of 2.8 µg/kg) 
was similar to previous findings, but time to peak concentration was slightly shorter. 
There was, however, high variability in Tmax. Moreover, the patients examined by 
Miller et al. had congenital heart disease and were anesthetized and supine during 
administration of intranasal dexmedetomidine, which could all have affected the 
disposition of dexmedetomidine (Miller et al. 2018). 
We hypothesized that intranasal doses of 2-3 µg/kg of dexmedetomidine would lead 
to clinically efficacious plasma concentrations in children. Some previous studies 
have indicated that dexmedetomidine plasma concentrations between 0.3 and 0.8 
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ng/ml are required to provide mild to moderate sedation in pediatric patients and 
adults, respectively (Potts et al. 2009, Ebert et al. 2000, Yoo et al. 2015). The mean 
Cmax in our study was 0.54 ng/ml, suggesting that sedative concentrations are 
achieved after intranasal 2-3 µg/kg doses of dexmedetomidine. However, almost all 
patients required additional sedation with thiopental. Moreover, concentration-time 
profiles indicated that the plasma concentrations of dexmedetomidine decrease quite 
rapidly, which suggests that higher initial doses or repeated dosing may be needed 
for clinical efficacy for longer procedures.  
Our findings suggest that there was no difference in the sedative effects of 
dexmedetomidine between the different age groups. The average decline in CBSS 
was 8 points from the baseline and maximal reductions were recorded 45 min after 
dosing in all three age categories. This can be considered as clinically acceptable 
sedation, as decreases of 6 or more CBSS points have been demonstrated to represent 
a good response to sedative agents in pediatric patients (Boerlage et al. 2015). 
Based on the present and some previous findings, the optimal dose of intranasal 
dexmedetomidine for ambulatory sedation of pediatric patients may be at least 3 
µg/kg (Mekitarian Filho et al. 2015, Baier et al. 2016). Our results indicate that 
dexmedetomidine concentrations in plasma declined relatively rapidly also after 
intranasal dosing. Higher doses may be needed to prolong the sedative effect. On the 
other hand, the time to discharge might then be prolonged, and further studies will 
be needed in order to define the optimal dosing of intranasal dexmedetomidine. 
Intranasally administered dexmedetomidine as the sole agent might not be sufficient 
for MRI sedation of pediatric patients, and combinations with other sedative agents, 
mainly GABAA receptor modulators, may be needed. 
6.4  Barbiturate sparing effect of intranasally administered 
dexmedetomidine 
Some previous studies have retrospectively evaluated the effect of dexmedetomidine 
on propofol consumption in pediatric MRI sedation (Boriosi et al. 2017, Nagoshi et 
al. 2018), but as far as we are aware, this is the first study to have investigated the 
impact of premedication with intranasally administered dexmedetomidine on 
barbiturate (thiopental) requirements for procedural MRI sedation of children. In 
previous studies, pediatric patients were sedated for MRI with intravenous propofol 
with or without 0.5-2 µg/kg doses of intravenous dexmedetomidine. In both studies, 
the use of dexmedetomidine as part of the sedation regimen reduced propofol 
consumption and airway complications compared to the control group.  
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Our results suggest that significantly less thiopental is needed for sedation of 
children for MRI when intranasal dexmedetomidine is used as premedication. Before 
the use of intranasal dexmedetomidine, supplemental oxygen has had to be provided 
to a significant number of patients. Considering the fact that thiopental may cause 
respiratory depression and other adverse effects, then a substantially reduced 
consumption of thiopental is considered to be beneficial and may reduce the risk of 
adverse events in MRI sedation of children. Even though 33% of the control group 
patients (but only 2% of the dexmedetomidine patients) received supplemental 
oxygen, peripheral blood oxygen saturation was lower in the control group. This 
suggests that the use of intranasal dexmedetomidine as premedication may protect 
patients from the hypercapnia and respiratory depression sometimes evoked by 
oxygen administration. 
Almost all (98%) of the patients in the dexmedetomidine group received thiopental 
due to emergence and anxiety during transfer from their hospital bed to the MRI 
room. To reduce the need of additional sedation after intranasal dexmedetomidine, 
it might be worthwhile to wait until the patient falls asleep again on the MRI bed. 
The use of two sedative agents with two different mechanisms of action for sedation 
in pediatric patients undergoing MRI appears to represent a safe protocol with 
respect to preserving adequate respiration and maintaining hemodynamic control. 
The use of intranasal dexmedetomidine as premedication does not, however, appear 
to totally eliminate the need for GABAA receptor modulators. 
6.5  Opioid sparing effect of intranasally administered 
dexmedetomidine 
Study IV demonstrated that intraoperatively administered intranasal low-dose 
dexmedetomidine reduced opioid requirement in patients undergoing total hip 
arthroplasty. Previously, the use of intravenous dexmedetomidine as intraoperative 
adjunct has been shown to reduce postoperative pain and opioid consumption in 
orthopedic surgical procedures (Kim et al. 2017, Shin et al. 2018), but the intranasal 
administration route of dexmedetomidine has never been investigated in this patient 
population.  
The rationale for the intraoperative use of extravascular dexmedetomidine instead of 
intravenous dosing is to avoid the latter’s adverse hemodynamic effects (Iirola et al. 
2011a). Perioperative administration of intranasal dexmedetomidine has been mostly 
studied in pediatric patients and only a few studies on adult patients have been 
conducted. In these previous studies, the employed dose of intranasal 
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dexmedetomidine was higher (1.5-2.0 µg/kg) than in our study (Nooh et al. 2013, 
Lu et al. 2016, Qiao et al. 2016). 
In previous studies in patients undergoing total hip arthroplasty, clinically 
meaningful morphine‐sparing effects of other analgesic adjuvants have been 
considered to be 10-15 mg of intravenous morphine over 48 h postoperatively 
(Kardash et al. 2008). Thus, the difference found in our study (26 mg of oral 
morphine) may be considered as clinically significant. 
The anesthetic sparing effect of dexmedetomidine may be reflected in entropy (Iirola 
et al. 2011, Kim et al. 2017). We used relatively low doses of intranasal 
dexmedetomidine, which did not have statistically significant effects on 
intraoperative SE levels. However, the use of intraoperative vasoactive medication 
was higher in the dexmedetomidine group, suggesting that there may be a slightly 
lower need for intraoperative administration of propofol and remifentanil after 
administration of intranasal dexmedetomidine. 
We included relatively healthy adult patients in our study and were not able to 
monitor postoperative delirium, but it would be interesting to examine whether 
intranasally administered low-dose dexmedetomidine could exert a beneficial impact 
on postoperative delirium in elderly and cognitively impaired patients undergoing 
total hip arthroplasty. 
Our study revealed that use of intranasal low-dose dexmedetomidine as an 
intraoperative adjunct in supine anesthetized patients undergoing total hip 
arthroplasty has clinically significant effects on postoperative opioid consumption, 
accompanied by rather minor hemodynamic side effects. Postoperative opioid 
consumption is a common concern of all care providers. An appreciation of the 
benefits of opioid sparing techniques and multimodal analgesia will help physicians 
to improve postoperative pain management. 
6.6  Hemodynamic and sympatholytic effects of dexmedetomidine 
Dexmedetomidine has effects on HR and blood pressure, which is probably the main 
reason restricting its use outside of operation rooms and ICUs. Many studies have 
shown that dexmedetomidine causes individually variable, biphasic responses in 
blood pressure as well as the decrease in HR due to its vasoconstrictive and 
sympatholytic effects. The best known side effect of dexmedetomidine is 
bradycardia, and previous studies have indicated that dexmedetomidine decreases 
HR by 15-20% from the baseline (Ebert et al 2000, Mason and Lerman 2011). We 
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observed similar decreases in HR in all studies, but in most cases, the decreases in 
HR did not require any interventions. In Studies III and IV, the use of 
dexmedetomidine was compared to a control group and statistically significant 
differences were observed in HR, but with no clinically significant impact on patient 
care.  
Especially in pediatric patients, reductions in HR may cause concern, since cardiac 
output of newborns and infants has been traditionally considered to be HR dependent 
(Mason and Lönnqvist 2015). However, already three decades ago it was 
demonstrated that even newborns are capable of increasing their cardiac output by 
augmenting their stroke volume (Vinberg and Lundell 1990). The HR slowing effect 
of dexmedetomidine is actually very similar to natural sleep, which has been 
observed to reduce HR by 15-20% from awake levels (Montague et al. 1982, 
Fleming et al. 2011). In view of the fact that dexmedetomidine induces a kind of 
drug-induced sedation mimicking natural sleep, the reductions in HR may be 
considered, at least partly, physiological. Although combined with thiopental 
administration, our results in Studies II and III showed that intranasal use of 2-3 
µg/kg doses of dexmedetomidine decreased HR on the average by 16 bpm (by 8.9%). 
In both studies, HR was reduced most in our youngest patients (0-2 years of age). 
Despite the rather small reductions in HR in our studies, safety trials regarding the 
intranasal use of dexmedetomidine are lacking, and HR as well as signs of 
hypoperfusion should be closely monitored when administering dexmedetomidine 
to infants. 
In Study I, a dose of 1 µg/kg dexmedetomidine administered either subcutaneously 
or intravenously did not cause any signs of hypotension or hypoperfusion in the 
healthy volunteer subjects. The subjects were, however, kept in a supine position for 
at least 4 hours after dexmedetomidine dosing and we cannot rule out that 
dexmedetomidine-induced sympatholysis could have triggered orthostatic reactions. 
Thus, it is safer to keep patients in the supine position for at least the duration of the 
drug’s sedative effects. 
We observed significantly lower MAP in Study I at 0-120 min after intravenous 
dosing compared to subcutaneous dosing. This coincided with plasma noradrenaline 
concentrations that remained significantly lower during the entire sampling period 
after intravenous compared to subcutaneous administration. Considering the 
possible use of subcutaneous administration in palliative care, where hemodynamic 
monitoring may be challenging or lacking, these findings are favourable. 
In Study IV, we observed lower postoperative HR and MAP in the dexmedetomidine 
group, suggesting that the hemodynamic effects of intranasally administered 
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dexmedetomidine are significant even at doses of 0.5-1.0 µg/kg. Compared to the 
control group, there was no difference in PACU time. Furthermore, hemodynamic 
parameters remained clinically acceptable and no vasoactive treatments were needed 
in the postoperative care of the dexmedetomidine-treated patients. Together with its 
analgesic effect, the sympatholytic properties of dexmedetomidine may help to 
reduce perioperative bleeding and may be beneficial for patients with ischemic heart 
disease. On the other hand, the reduced MAP as compared to the control group could 
impair diuresis. Since dexmedetomidine has also diuresis enhancing properties, it 
would have been interesting to compare urine output between the groups, but since 
the patients undergoing total hip arthroplasty had not been implanted with urinary 
catheters, we were not able to assess diuresis. 
6.7  Sedative effects of dexmedetomidine 
In Study I, the subjective scores for vigilance and performance were significantly 
lower at 0-60 min if the drug had been injected intravenously in comparison with its 
subcutaneous dosing. At later time points, the subjects tended to be more sedated 
after subcutaneous administration, but the difference was not statistically significant. 
The sedative effects of intranasal administration of dexmedetomidine in children 
undergoing surgery have already been documented by others. Our findings regarding 
the sedative effects of intranasal dexmedetomidine in Studies II and III are similar 
to previous results published for pediatric patients (Kim et al. 2017). Our results 
suggest that the use of intranasal dexmedetomidine in pediatric patients for MRI 
sedation is a useful adjuvant modality in this patient population, but might not alone 
be sufficient for procedural MRI sedation of pediatric patients. Sedation with 
dexmedetomidine resembles physiological sleep and maintains the patient in an 
arousable state, which may actually be problematic in procedures where the patient 
is expected to remain immobile. Patients sedated for MRI should, however, be 
arousable soon after the procedure so that they can be discharged from the imaging 
unit. Thus, the use of dexmedetomidine as part of sedation appears reasonable. 
Determining the optimal dose, drug concentration and the drug delivery system for 
intranasal dexmedetomidine dosing are topics for future investigations. 
Dexmedetomidine has analgesic and amnestic effects and it has been shown that its 
use as an anesthetic adjunct has similar effects as propofol on the bispectral index 
and entropy (Patel et al. 2012). In Study IV, the sedative effects of dexmedetomidine 
were monitored with SE, but no statistically significant differences in SE levels or 
in the need for other anesthetics were observed in comparison to the control group. 
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There was, however, a tendency to lower SE levels and to reduce the need for 
propofol and remifentanil in the dexmedetomidine group. Probably, the use of larger 
doses of dexmedetomidine as an anesthetic adjunct would emphasize the difference. 
In order to avoid intraoperative awareness, monitoring of the depth of sedation with 
entropy or with the bispectral index is warranted when dexmedetomidine is used as 
a general anesthesia adjunct. 
6.8  Safety of extravascularly administered dexmedetomidine 
In Study I, one participant experienced asymptomatic bradycardia of 32–39 bpm, 
which emerged 60 min after subcutaneous administration of dexmedetomidine. He 
was a tall athlete with a low resting HR of 40–42 bpm. The results of previous studies 
indicate that dexmedetomidine causes significant cardiac conduction effects via 
depression of the sinoatrial node, thus decreasing resting HR by up to 15–20% (Ebert 
et al. 2000). Even if the change in HR was not unexpected, we decided to exclude 
this subject from the intravenous administration phase to avoid the risk of severe 
bradycardia. In spite of the observed bradycardia, the blood pressure of the excluded 
subject remained acceptable. The other nine subjects exhibited no significant adverse 
effects.  
In Studies II and III, two patients receiving intranasal dexmedetomidine displayed 
significant bradycardia soon after dosing of intravenous thiopental. Although 
previous studies indicate that active correction of bradycardia in pediatric patients 
after dexmedetomidine dosing may cause hypertension (Subramanyam et al. 2015), 
our patient was given atropine to increase the HR. We observed no serious adverse 
effects related to bradycardia or with the combined dosing of dexmedetomidine and 
atropine. Dexmedetomidine was well tolerated and only transient adverse effects 
were recorded. Intranasal doses were easy to deliver to the patients, and drug 
administration was always accomplished. No bleeding or local irritation was 
observed or reported by the patients. These findings suggest that the intranasal route 
may be a safe mode of dexmedetomidine administration. 
In Study IV, the employed dexmedetomidine dose was relatively low and 
dexmedetomidine was not expected to cause any hemodynamic or other adverse 
effects. Although when used as an intraoperative adjunct, dexmedetomidine may 
cause prolonged postoperative sedation, intranasal doses of 0.5-1.0 µg/kg did not 
have any effects on the PACU time as compared to the control group. 
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6.9  Limitations of the studies 
The limitations to Studies I and II include the short sampling period for 
dexmedetomidine plasma samples, since dexmedetomidine concentrations remained 
high in both studies after extravascular dosing. Study I included only healthy young 
male volunteers. The main limitation of Study II is the lack of complete 
standardization in the dosing regimens. The administration of thiopental was at the 
discretion of the attending anesthesiologist. The sampling time was only 4 hours and 
a total of 6 blood samples were collected during this time, whereas in Study I sixteen 
samples were collected over 10 hours. It would have been more informative to 
collect further blood samples in both studies to determine dexmedetomidine 
elimination after subcutaneous and intranasal administration. 
To evaluate the sympatholytic effects caused by dexmedetomine more precisely, it 
would have been beneficial to monitor blood pressure in Studies II and III. Since a 
patient sedated with dexmedetomidine is easily arousable, non-invasive blood 
pressure monitoring with cuff inflation may awaken the patient and therefore we 
were not able to routinely measure blood pressure in the pediatric patients 
undergoing MRI procedures.  
The retrospective design of Studies III and IV could have affected the results, even 
though consecutive patients were systematically collected in order to avoid any 
selection bias. A relatively new sedation protocol was used in both studies at the time 
when the patients in the dexmedetomidine group were treated and protocol was 
changed during the study. This might have influenced the outcomes as the personnel 
sedating children for MRI and the personnel treating patients undergoing total hip 
arthroplasty were still collecting experience on the use of intranasal 
dexmedetomidine. On the other hand, only a very limited numbers of 
anesthesiologists and other staff were in charge of all of the patients in Studies III 
and IV.  
The dose of dexmedetomidine used in Study IV was relatively small, which may 
have limited its effects, especially with respect to secondary outcomes. Intranasal 
dexmedetomidine was administered to supine patients, which could have affected 
drug absorption. However, a recent published pharmacokinetic study conducted in 
anesthetized pediatric patients undergoing heart surgery and receiving intranasal 
dexmedetomidine in the supine position, reported that the drug’s relative 
bioavailability was 84% (Miller et al. 2018). 
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6.10  Ethical considerations 
The aims of our prospective studies – to characterize the pharmacokinetics, 
bioavailability, sedative effects and local tolerability of subcutaneously and 
intranasally administered dexmedetomidine in healthy volunteers and in pediatric 
patients, respectively – were scientifically sound and ethically justified. The 
investigators were aware of the ethical issues and risks associated with the study 
procedures. 
The doses of dexmedetomidine employed in Studies I-IV were based on previous 
studies and were not considered to exert any marked effects on respiration and blood 
oxygen saturation. Small transient decreases in blood pressure and simultaneous 
decreases in HR were expected when dexmedetomidine was administered, especially 
intravenously.  
In Study I, the hemodynamic effects were assessed as being non-symptomatic but 
the subjects were kept in semi-recumbent position during the first 3 hours after 
dexmedetomidine administration. A qualified physician experienced in 
anesthesiology was present during the study sessions and monitored continuously 
the safety and clinical well-being of the subjects. The study procedures included 
cannulation of a vein and an artery, which were not considered to constitute a 
significant health hazard to the subjects. A total volume of less than 300 ml of blood 
was drawn from each subject during the study sessions. 
In Study II, the patients received intranasal dexmedetomidine and underwent venous 
cannulation as part of their care, regardless of whether or not the patient was 
participating in the study. Blood sampling was not considered to constitute a 
significant health hazard to the patients, since an amount less than 1% of total blood 
volume was drawn from each patient during the study for plasma dexmedetomidine 
analysis. A qualified physician experienced in pediatric anesthesiology was present 
during the study sessions and monitored the safety and well-being of the patients. 
The patients were only discharged after they were assessed as being fit for safe 
discharge in the investigator's opinion. All patients and their guardians were 
appropriately informed of the discomforts and possible risks associated with this 
study and were free to withdraw their consent at any time without loss of health care 
or other benefits. Studies III-IV were retrospective studies that did not have any 
impact on patient care. Relatively new treatments were studied in both studies, which 
is ethically justified and may increase the safety of patient care. 
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6.11  Future studies 
The pharmacodynamic effects of extravascularly administered dexmedetomidine 
have been studied earlier with several administration routes and with various 
dosages. Our studies mainly focused on intranasal administration, which appears to 
be the most popular route. Intranasal administration of dexmedetomidine is off-label, 
but its use is becoming increasingly popular as a premedication and intraoperative 
adjunct. Subcutaneous administration of dexmedetomidine is relatively new and 
more studies are warranted to clarify its pros and cons. 
A drug solution with a higher dexmedetomidine concentration would be beneficial 
regarding extravascular dosing. Only one injectable formulation of 
dexmedetomidine is commercially available (100 µg/ml), and the dosing volumes 
often exceed the recommended volumes for intranasal administration. It should be 
further investigated whether doses greater than 3 µg/kg have similar bioavailabilities 
as doses of 1 and 2 µg/kg. It would also be interesting to study the concentration of 
dexmedetomidine in cerebrospinal fluid, since it has been claimed that intranasal 
drug administration may allow direct absorption of the drug into the central nervous 
system (Khan et al. 2017). 
Subcutaneous administration of sedative and analgesic drugs has been widely used 
in palliative care (Thomas et al. 2015). The slow onset of effects after subcutaneous 
administration of dexmedetomidine could be beneficial by providing prolonged 
sedation for patients in palliative care, obviating the need for intravenous 
administration. Our results suggest that subcutaneous administration of 
dexmedetomidine could be a useful addition to the armament of drugs used for 
palliative sedation. Analgesic and opioid-sparing effects of dexmedetomidine may 
be beneficial for palliative care patients with opioid hyperalgesia. Furthermore, 
dexmedetomidine may reduce the likelihood of delirium, at least when compared to 
sedation with propofol or benzodiazepines. However, we investigated healthy 
volunteers, and no placebo control session was included in the study. Only a few 
case reports regarding the use of dexmedetomidine in palliative care have been 
published (Hilliard et al. 2015, O´Hara et al. 2015), and it should be further 
investigated whether subcutaneously administered dexmedetomidine is a feasible 
way to sedate patients in end-of-life care. Although our results may encourage the 
use of subcutaneous administration of dexmedetomidine, our findings should be 
considered as preliminary, and further trials are warranted. Furthermore, 
dexmedetomidine pharmacokinetics after continuous or model-informed 
subcutaneous infusions should be evaluated. 
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Intranasal administration of dexmedetomidine is off-label use, as in fact is all kind 
of use of this drug in pediatric patients. Due to the feasibility, safety and ease of 
administration of intranasal dexmedetomidine, its use is increasing as a 
premedication and as an intraoperative adjunct. A recent retrospective study 
evaluated the usefulness of an intranasally administered dexmedetomidine-ketamine 
combination in sedation of more than 16 000 pediatric patients undergoing MRI. The 
sedation protocol was found to be associated with acceptable efficacy and low rates 
of adverse events (Yang et al. 2019). The combination of dexmedetomidine and 
ketamine appears to be a promising way to treat anxiety and pain in both pediatric 
and adult patients. Both drugs have good bioavailabilities after intranasal 
administration. Clearly, further studies on the use of dexmedetomidine-ketamine 
combinations are warranted. 
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VII  SUMMARY AND CONCLUSIONS 
The results of the clinical investigations presented in this thesis give rise to the 
following conclusions: 
1.  The average bioavailability of subcutaneously administered dexmedetomidine 
was good (81%), but the interindividual variation was large. Subcutaneously 
administered dexmedetomidine was efficacious and well tolerated. For 
patients requiring light sedation, subcutaneous administration of 
dexmedetomidine may be a feasible alternative, since this route was 
associated with attenuated sympatholysis as compared to intravenous 
administration. According to our results, subcutaneous dexmedetomidine 
should be administered 60-90 min prior to the desired maximal effect. 
2.  The pharmacometric model developed for subcutaneously dosed 
dexmedetomidine indicates that the local fat compartment might slow down 
drug absorption from the subcutaneous site of injection. Even if the 
pharmacodynamic effects of dexmedetomidine are more subtle after 
subcutaneous dosing, further model-based studies will be needed to evaluate 
the clinical significance of this finding. 
3.  Our results demonstrated that intranasally administered dexmedetomidine at 
doses of 2-3 µg/kg was relatively rapidly absorbed and achieved acceptable 
sedation in pediatric patients requiring ambulatory sedation. Intranasal 
dexmedetomidine exhibited rather similar properties in pediatric patients as 
encountered in adults, but peak concentrations and exposure to the drug 
appeared to decrease with age. Further studies on the optimal dosage and 
delivery methods of intranasal dexmedetomidine for procedural MRI sedation 
appear warranted. 
4.  Intranasal dexmedetomidine markedly reduced the requirement of thiopental in 
ambulatory sedation of pediatric patients. Compared to sedation with thiopental 
alone, the use of intranasal dexmedetomidine as premedication attenuates 
sympathoadrenal stress responses, does not compromise respiration, and has an 
excellent recovery profile in MRI sedation of pediatric patients.  
5.  Intranasal dexmedetomidine administered in doses as low as 0.5-1.0 µg/kg 
decreased postoperative opioid consumption in adult patients undergoing total 
hip arthroplasty. Our results represent a basis for further clarification of the 
dose-response of intranasal dexmedetomidine with respect to postoperative 
analgesia in surgical patients.
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